EP2139522A2 - Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers - Google Patents
Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancersInfo
- Publication number
- EP2139522A2 EP2139522A2 EP08731532A EP08731532A EP2139522A2 EP 2139522 A2 EP2139522 A2 EP 2139522A2 EP 08731532 A EP08731532 A EP 08731532A EP 08731532 A EP08731532 A EP 08731532A EP 2139522 A2 EP2139522 A2 EP 2139522A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- moieties
- independently selected
- alkyl
- cancer
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 76
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 29
- 230000009826 neoplastic cell growth Effects 0.000 title claims abstract description 26
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 21
- 235000006708 antioxidants Nutrition 0.000 title abstract description 23
- 150000001875 compounds Chemical class 0.000 title description 106
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 28
- 201000010099 disease Diseases 0.000 title description 24
- 125000002091 cationic group Chemical group 0.000 title description 15
- 210000003470 mitochondria Anatomy 0.000 title description 14
- 230000003463 hyperproliferative effect Effects 0.000 title description 4
- 230000002265 prevention Effects 0.000 title description 4
- 238000002560 therapeutic procedure Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 92
- 150000003839 salts Chemical class 0.000 claims abstract description 87
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 37
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 37
- 150000001768 cations Chemical group 0.000 claims abstract description 33
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims abstract description 29
- -1 amino, methylamino, dimethylamino Chemical group 0.000 claims description 101
- 125000000217 alkyl group Chemical group 0.000 claims description 57
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 56
- 125000004432 carbon atom Chemical group C* 0.000 claims description 44
- 201000011510 cancer Diseases 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 32
- 150000001450 anions Chemical class 0.000 claims description 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 26
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 150000002367 halogens Chemical class 0.000 claims description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 22
- 229910052698 phosphorus Inorganic materials 0.000 claims description 22
- 239000002243 precursor Substances 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- 125000004437 phosphorous atom Chemical group 0.000 claims description 21
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 206010027476 Metastases Diseases 0.000 claims description 17
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 17
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 17
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 17
- 210000002307 prostate Anatomy 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 230000009401 metastasis Effects 0.000 claims description 16
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 16
- 206010020718 hyperplasia Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000005647 linker group Chemical group 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 13
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 229940002612 prodrug Drugs 0.000 claims description 5
- 239000000651 prodrug Substances 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 3
- 150000004820 halides Chemical class 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 229920001281 polyalkylene Polymers 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 2
- LIRCFGBNQPWVRY-UHFFFAOYSA-K aluminum;2-methyl-4-oxopyran-3-olate Chemical compound [Al+3].CC=1OC=CC(=O)C=1[O-].CC=1OC=CC(=O)C=1[O-].CC=1OC=CC(=O)C=1[O-] LIRCFGBNQPWVRY-UHFFFAOYSA-K 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- 125000006177 alkyl benzyl group Chemical group 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 64
- 210000004027 cell Anatomy 0.000 description 47
- 150000003254 radicals Chemical class 0.000 description 47
- 239000000203 mixture Substances 0.000 description 45
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 42
- 239000002904 solvent Substances 0.000 description 36
- 239000000243 solution Substances 0.000 description 34
- 238000010992 reflux Methods 0.000 description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- 238000002360 preparation method Methods 0.000 description 28
- 230000036542 oxidative stress Effects 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- 125000001424 substituent group Chemical group 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 19
- 239000003642 reactive oxygen metabolite Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 11
- 239000003098 androgen Substances 0.000 description 11
- 230000035755 proliferation Effects 0.000 description 11
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- RPDUDBYMNGAHEM-UHFFFAOYSA-N PROXYL Chemical group CC1(C)CCC(C)(C)N1[O] RPDUDBYMNGAHEM-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical class CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 9
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 150000004714 phosphonium salts Chemical group 0.000 description 8
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 239000002417 nutraceutical Substances 0.000 description 7
- 235000021436 nutraceutical agent Nutrition 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 125000003107 substituted aryl group Chemical group 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- LRTRXDSAJLSRTG-UHFFFAOYSA-N 4-bromobutanoyl chloride Chemical compound ClC(=O)CCCBr LRTRXDSAJLSRTG-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 125000005431 alkyl carboxamide group Chemical group 0.000 description 6
- 238000013270 controlled release Methods 0.000 description 6
- 125000005432 dialkylcarboxamide group Chemical group 0.000 description 6
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 208000023958 prostate neoplasm Diseases 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 150000001335 aliphatic alkanes Chemical class 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000005779 cell damage Effects 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 230000002438 mitochondrial effect Effects 0.000 description 5
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 125000005415 substituted alkoxy group Chemical group 0.000 description 5
- 125000000547 substituted alkyl group Chemical group 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- XYJODUBPWNZLML-UHFFFAOYSA-N 5-ethyl-6-phenyl-6h-phenanthridine-3,8-diamine Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2N(CC)C1C1=CC=CC=C1 XYJODUBPWNZLML-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
- QYTDEUPAUMOIOP-UHFFFAOYSA-N TEMPO Chemical group CC1(C)CCCC(C)(C)N1[O] QYTDEUPAUMOIOP-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 230000002280 anti-androgenic effect Effects 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 239000000051 antiandrogen Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 150000007942 carboxylates Chemical class 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000003271 compound fluorescence assay Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000004438 haloalkoxy group Chemical group 0.000 description 4
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 150000007529 inorganic bases Chemical class 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 125000005496 phosphonium group Chemical group 0.000 description 4
- 239000003880 polar aprotic solvent Substances 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 208000017497 prostate disease Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 229940086542 triethylamine Drugs 0.000 description 4
- GTQHJCOHNAFHRE-UHFFFAOYSA-N 1,10-dibromodecane Chemical compound BrCCCCCCCCCCBr GTQHJCOHNAFHRE-UHFFFAOYSA-N 0.000 description 3
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 239000007832 Na2SO4 Substances 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 150000004703 alkoxides Chemical class 0.000 description 3
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 3
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001033 ether group Chemical group 0.000 description 3
- 150000002170 ethers Chemical class 0.000 description 3
- 150000002334 glycols Chemical class 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 150000002391 heterocyclic compounds Chemical class 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- OXUCOTSGWGNWGC-UHFFFAOYSA-N octane Chemical compound CCCCCCC[CH2-] OXUCOTSGWGNWGC-UHFFFAOYSA-N 0.000 description 3
- 150000002891 organic anions Chemical class 0.000 description 3
- 230000004792 oxidative damage Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000004001 thioalkyl group Chemical group 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000008836 DNA modification Effects 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 229940022663 acetate Drugs 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 150000001767 cationic compounds Chemical class 0.000 description 2
- 201000007455 central nervous system cancer Diseases 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000007323 disproportionation reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 150000002443 hydroxylamines Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910001412 inorganic anion Inorganic materials 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 230000004898 mitochondrial function Effects 0.000 description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000006606 n-butoxy group Chemical group 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 238000011620 noble rat Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000006215 rectal suppository Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000005920 sec-butoxy group Chemical group 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 239000006217 urethral suppository Substances 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- HFVIYAZBVIGNAN-UHFFFAOYSA-N 1,1-dibromodecane Chemical compound CCCCCCCCCC(Br)Br HFVIYAZBVIGNAN-UHFFFAOYSA-N 0.000 description 1
- RBBNTRDPSVZESY-UHFFFAOYSA-N 1,10-dichlorodecane Chemical compound ClCCCCCCCCCCCl RBBNTRDPSVZESY-UHFFFAOYSA-N 0.000 description 1
- CKJCTZAIDVFHCX-UHFFFAOYSA-N 1,10-diiododecane Chemical compound ICCCCCCCCCCI CKJCTZAIDVFHCX-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- KJDRSWPQXHESDQ-UHFFFAOYSA-N 1,4-dichlorobutane Chemical compound ClCCCCCl KJDRSWPQXHESDQ-UHFFFAOYSA-N 0.000 description 1
- ROUYUBHVBIKMQO-UHFFFAOYSA-N 1,4-diiodobutane Chemical compound ICCCCI ROUYUBHVBIKMQO-UHFFFAOYSA-N 0.000 description 1
- IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 1
- LBKDGROORAKTLC-UHFFFAOYSA-N 1,5-dichloropentane Chemical compound ClCCCCCCl LBKDGROORAKTLC-UHFFFAOYSA-N 0.000 description 1
- IAEOYUUPFYJXHN-UHFFFAOYSA-N 1,5-diiodopentane Chemical compound ICCCCCI IAEOYUUPFYJXHN-UHFFFAOYSA-N 0.000 description 1
- SGRHVVLXEBNBDV-UHFFFAOYSA-N 1,6-dibromohexane Chemical compound BrCCCCCCBr SGRHVVLXEBNBDV-UHFFFAOYSA-N 0.000 description 1
- OVISMSJCKCDOPU-UHFFFAOYSA-N 1,6-dichlorohexane Chemical compound ClCCCCCCCl OVISMSJCKCDOPU-UHFFFAOYSA-N 0.000 description 1
- LVWSZGCVEZRFBT-UHFFFAOYSA-N 1,7-dibromoheptane Chemical compound BrCCCCCCCBr LVWSZGCVEZRFBT-UHFFFAOYSA-N 0.000 description 1
- PSEMXLIZFGUOGC-UHFFFAOYSA-N 1,7-dichloroheptane Chemical compound ClCCCCCCCCl PSEMXLIZFGUOGC-UHFFFAOYSA-N 0.000 description 1
- ZZHWQLNCPAJXJE-UHFFFAOYSA-N 1,7-diiodoheptane Chemical compound ICCCCCCCI ZZHWQLNCPAJXJE-UHFFFAOYSA-N 0.000 description 1
- DKEGCUDAFWNSSO-UHFFFAOYSA-N 1,8-dibromooctane Chemical compound BrCCCCCCCCBr DKEGCUDAFWNSSO-UHFFFAOYSA-N 0.000 description 1
- WXYMNDFVLNUAIA-UHFFFAOYSA-N 1,8-dichlorooctane Chemical compound ClCCCCCCCCCl WXYMNDFVLNUAIA-UHFFFAOYSA-N 0.000 description 1
- KZDTZHQLABJVLE-UHFFFAOYSA-N 1,8-diiodooctane Chemical compound ICCCCCCCCI KZDTZHQLABJVLE-UHFFFAOYSA-N 0.000 description 1
- WGAXVZXBFBHLMC-UHFFFAOYSA-N 1,9-dibromononane Chemical compound BrCCCCCCCCCBr WGAXVZXBFBHLMC-UHFFFAOYSA-N 0.000 description 1
- JMGRNJZUQCEJDB-UHFFFAOYSA-N 1,9-dichlorononane Chemical compound ClCCCCCCCCCCl JMGRNJZUQCEJDB-UHFFFAOYSA-N 0.000 description 1
- QVXLFUVDXDMDFE-UHFFFAOYSA-N 1,9-diiodononane Chemical compound ICCCCCCCCCI QVXLFUVDXDMDFE-UHFFFAOYSA-N 0.000 description 1
- JXOSPTBRSOYXGC-UHFFFAOYSA-N 1-Chloro-4-iodobutane Chemical compound ClCCCCI JXOSPTBRSOYXGC-UHFFFAOYSA-N 0.000 description 1
- WIKLZASKGKBLQT-UHFFFAOYSA-N 1-azido-4-chlorobutane Chemical compound ClCCCCN=[N+]=[N-] WIKLZASKGKBLQT-UHFFFAOYSA-N 0.000 description 1
- AMJBCNIDVLQCBR-UHFFFAOYSA-N 1-bromo-10-chlorodecane Chemical compound ClCCCCCCCCCCBr AMJBCNIDVLQCBR-UHFFFAOYSA-N 0.000 description 1
- LEWJNYLBKFMXSX-UHFFFAOYSA-N 1-bromo-10-iododecane Chemical compound BrCCCCCCCCCCI LEWJNYLBKFMXSX-UHFFFAOYSA-N 0.000 description 1
- NIDSRGCVYOEDFW-UHFFFAOYSA-N 1-bromo-4-chlorobutane Chemical compound ClCCCCBr NIDSRGCVYOEDFW-UHFFFAOYSA-N 0.000 description 1
- GFKIYVSAPHPZEJ-UHFFFAOYSA-N 1-bromo-4-iodobutane Chemical compound BrCCCCI GFKIYVSAPHPZEJ-UHFFFAOYSA-N 0.000 description 1
- PHHNNDKXQVKJEP-UHFFFAOYSA-N 1-bromo-5-chloropentane Chemical compound ClCCCCCBr PHHNNDKXQVKJEP-UHFFFAOYSA-N 0.000 description 1
- JTYUIAOHIYZBPB-UHFFFAOYSA-N 1-bromo-6-chlorohexane Chemical compound ClCCCCCCBr JTYUIAOHIYZBPB-UHFFFAOYSA-N 0.000 description 1
- YIMPISOHWYXINO-UHFFFAOYSA-N 1-bromo-6-iodohexane Chemical compound BrCCCCCCI YIMPISOHWYXINO-UHFFFAOYSA-N 0.000 description 1
- YJMLTXCVCADMHF-UHFFFAOYSA-N 1-chloro-10-iododecane Chemical compound ClCCCCCCCCCCI YJMLTXCVCADMHF-UHFFFAOYSA-N 0.000 description 1
- FDFVVBKRHGRRFY-UHFFFAOYSA-N 1-hydroxy-2,2,5,5-tetramethylpyrrolidine Chemical class CC1(C)CCC(C)(C)N1O FDFVVBKRHGRRFY-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- QERBYNSXUVOSBG-UHFFFAOYSA-N 10-bromodecanoyl 10-bromodecanoate Chemical compound BrCCCCCCCCCC(=O)OC(CCCCCCCCCBr)=O QERBYNSXUVOSBG-UHFFFAOYSA-N 0.000 description 1
- SLUVTMPFRJVSTA-UHFFFAOYSA-N 10-bromodecylsulfonylmethylbenzene Chemical compound BrCCCCCCCCCCS(=O)(=O)CC1=CC=CC=C1 SLUVTMPFRJVSTA-UHFFFAOYSA-N 0.000 description 1
- VFIBVOLQILBYJN-UHFFFAOYSA-N 10-chlorodecyl(diazonio)azanide Chemical compound ClCCCCCCCCCC[N-][N+]#N VFIBVOLQILBYJN-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- VUZNLSBZRVZGIK-UHFFFAOYSA-N 2,2,6,6-Tetramethyl-1-piperidinol Chemical group CC1(C)CCCC(C)(C)N1O VUZNLSBZRVZGIK-UHFFFAOYSA-N 0.000 description 1
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- MMNYKXJVNIIIEG-UHFFFAOYSA-N 3-(aminomethyl)-PROXYL Chemical group CC1(C)CC(CN)C(C)(C)N1[O] MMNYKXJVNIIIEG-UHFFFAOYSA-N 0.000 description 1
- AIQMYWZQFQQTIQ-UHFFFAOYSA-M 4-(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-yl)oxybutyl-triphenylphosphanium;bromide Chemical compound [Br-].C1C(C)(C)N(O)C(C)(C)CC1OCCCC[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 AIQMYWZQFQQTIQ-UHFFFAOYSA-M 0.000 description 1
- XUXUHDYTLNCYQQ-UHFFFAOYSA-N 4-amino-TEMPO Chemical compound CC1(C)CC(N)CC(C)(C)N1[O] XUXUHDYTLNCYQQ-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- UYEWUSDKYMQCOU-UHFFFAOYSA-N 5-chloropentylsulfonylmethylbenzene Chemical compound ClCCCCCS(=O)(=O)CC1=CC=CC=C1 UYEWUSDKYMQCOU-UHFFFAOYSA-N 0.000 description 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 1
- YGHBVLKUJCATPQ-UHFFFAOYSA-N 6-chlorohexylsulfonylmethylbenzene Chemical compound ClCCCCCCS(=O)(=O)CC1=CC=CC=C1 YGHBVLKUJCATPQ-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010051999 Anogenital dysplasia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical group N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229930188012 Bromoether Natural products 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 101000766096 Halorubrum sodomense Archaerhodopsin-3 Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102100020870 La-related protein 6 Human genes 0.000 description 1
- 108050008265 La-related protein 6 Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 108091028062 MtDNA control region Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101000957678 Mus musculus Cytochrome P450 7B1 Proteins 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 1
- 101710084411 POU domain, class 2, transcription factor 2 Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102000007456 Peroxiredoxin Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229920000037 Polyproline Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000025844 Prostatic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000957679 Rattus norvegicus 25-hydroxycholesterol 7-alpha-hydroxylase Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 1
- 229960004103 abiraterone acetate Drugs 0.000 description 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 150000001449 anionic compounds Chemical group 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- HJCMMOODWZOXML-UHFFFAOYSA-N bromo hypobromite Chemical compound BrOBr HJCMMOODWZOXML-UHFFFAOYSA-N 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- UOCJDOLVGGIYIQ-PBFPGSCMSA-N cefatrizine Chemical group S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](N)C=2C=CC(O)=CC=2)CC=1CSC=1C=NNN=1 UOCJDOLVGGIYIQ-PBFPGSCMSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 229910000151 chromium(III) phosphate Inorganic materials 0.000 description 1
- IKZBVTPSNGOVRJ-UHFFFAOYSA-K chromium(iii) phosphate Chemical compound [Cr+3].[O-]P([O-])([O-])=O IKZBVTPSNGOVRJ-UHFFFAOYSA-K 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960004766 estradiol valerate Drugs 0.000 description 1
- ADFOJJHRTBFFOF-RBRWEJTLSA-N estramustine phosphate Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 ADFOJJHRTBFFOF-RBRWEJTLSA-N 0.000 description 1
- 229960004750 estramustine phosphate Drugs 0.000 description 1
- 229960003399 estrone Drugs 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- YPQLFJODEKMJEF-UHFFFAOYSA-N hydroxyflutamide Chemical compound CC(C)(O)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 YPQLFJODEKMJEF-UHFFFAOYSA-N 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 210000005061 intracellular organelle Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 1
- AHNJTQYTRPXLLG-UHFFFAOYSA-N lithium;diethylazanide Chemical compound [Li+].CC[N-]CC AHNJTQYTRPXLLG-UHFFFAOYSA-N 0.000 description 1
- YDGSUPBDGKOGQT-UHFFFAOYSA-N lithium;dimethylazanide Chemical compound [Li+].C[N-]C YDGSUPBDGKOGQT-UHFFFAOYSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- DVSDBMFJEQPWNO-UHFFFAOYSA-N methyllithium Chemical compound C[Li] DVSDBMFJEQPWNO-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000008599 nitrosative stress Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940026778 other chemotherapeutics in atc Drugs 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 108030002458 peroxiredoxin Proteins 0.000 description 1
- CMFNMSMUKZHDEY-UHFFFAOYSA-M peroxynitrite Chemical compound [O-]ON=O CMFNMSMUKZHDEY-UHFFFAOYSA-M 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 208000030761 polycystic kidney disease Diseases 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000005838 radical anions Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 230000010282 redox signaling Effects 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000013319 spin trapping Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012066 statistical methodology Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 1
- 229940006509 strontium-89 Drugs 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 125000005032 thiofuranyl group Chemical group S1C(=CC=C1)* 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 239000008181 tonicity modifier Substances 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940096973 urethral suppository Drugs 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
- 229960004982 vinblastine sulfate Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/54—Quaternary phosphonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Definitions
- inventions described herein relate to the treatment of various forms of cancer, or related neoplasias, with compounds that comprise one or more quaternary (check spelling) cationic moieties chemically linked to one or more anti-oxidant moieties comprising nitroxide or amine oxide moieties.
- Oxidative stress has been known to contribute to a variety of human degenerative diseases associated with aging, such as Parkinson's disease and Alzheimer's disease, as well as to Huntington's Chorea, diabetes and Friedreich's Ataxia (Allen, S., et al., J. Biol. Chem. 278:6371-6383,2003; Hirai, K., et al., J. Neurosci. 21:3017-3023, 2001) and to non-specific cellular damage that accumulates with aging.
- Mitochondria are the intracellular organelles primarily responsible for energy metabolism, and are also the major source of the free radicals and reactive oxygen species ("ROS", such as hydrogen peroxide and the superoxide radical anion (O 2 " )) that cause oxidative stress and/or damage inside most cells (Murphy MP, Smith RA., Ann. Rev Pharmacol Toxicol. 2006 Oct 2; Epub ahead of print). Mitochondria are equipped to detoxify hydrogen peroxide due to the presence of antioxidant enzymes (peroxiredoxins, thioredoxins, and GSH-dependent peroxidases (Chang, T. S., J. Biol. Chem. 279, 41975-41984, 2004).
- ROS free radicals and reactive oxygen species
- mitochondrial superoxide O 2
- MnSOD manganese superoxide dismutase
- oxidative damage can occur. This damage disrupts mitochondrial function and oxidative phosphorylation and leads to significant cellular damage to mitochondrial, cytoplasmic or nuclear cellular proteins, DNA, RNA and phospholipids and thus induces cell damage, death and/or disease.
- Superoxide can also react with nitric oxide at a diffusion-controlled reaction rate, forming a highly potent oxidant and peroxynitrite that can modify proteins and DNA through oxidation and nitration reactions (Beckman, J. S., et al., Nature 364, 584, 1993).
- ROS also act as a redox signaling molecule(s) and promotes cell proliferation, DNA damage repair errors and mutation leading to inflammatory hyper-proliferation, neoplasia and malignancy (see Michikawa et.al., "Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication.” Science. 1999 Oct 22;286(5440):774-9).
- ROS tissue reactive oxygen species
- antioxidant therapies To prevent the cellular damage caused by oxidative stress a number of prior art antioxidant therapies have been developed for treating various diseases resulting from oxidative stress. However, most of those inventions are not targeted to other organelles within cells or to the mitochondria and are therefore less than optimally effective.
- warhead groups are covalently coupled via linker groups to a bulky and/or lipophilic cationic moiety such as a quaternary ammonium or phosphonium cationic moiety. These compounds are initially absorbed and accumulate in the cytoplasmic region of cells in response to the negative plasma membrane potential of 30-60 mV (3).
- the lipophilic cations with a positive 30-6OmV potential permeate through the mitochondrion's lipid layers and selectively accumulate within mitochondria due to the larger mitochondrial membrane potential of 150-170 mV; (negative inside).
- Mitochondria-targeted compounds in this class of agents are shown below and include a mitochondria-directed ubiquinone (MitoQ) reported by Murphy and coworkers (U.S. Patent Nos. 6,331,532 and 7,232,809, and EP Patent 1 047 701 Bl, all of which are herein incorporated by reference in their entirety).
- MitoQ mitochondria-directed ubiquinone
- MitoQ has shown promise in the treatment of only some, but not all, oxidative stress induced diseases. MitoQ is currently undergoing Phase II clinical trials for the treatment of Parkinson's disease, but it has relatively minor activity against other oxidative stress-induced neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). This class of compounds is also disclosed in U.S. Published Application No. U.S. 2008/0032940, herein incorporated by reference in its entirety, in the context of methods for treating cancer.
- ALS Amyotrophic Lateral Sclerosis
- mitochondria-targeted compounds include mitochondria-targeted nitroxides, which have been used in method for treating neurodegenerative disorders (see U.S. Published Application No. 2007/0066572, herein incorporated by reference in its entirety) and mitochondria-targeted antioxidants, which have been used in methods for treating cancer (see U.S. Application No. 11/834,799, entitled “Methods for Reducing Anthracycline-Induced Toxicity,” filed August 7, 2007, herein incorporated by reference in its entirety).
- One aspect of the disclosure relates to methods for treating or inhibiting the occurrence, recurrence, progression or metastasis, of a cancer or a neoplastic or hyper- proliferative precursor thereof, consisting of administering to a mammal diagnosed as having a cancer or precursor neoplasia or hyper-proliferative disorder thereof, in an amount effective to treat the cancer or inhibit the occurrence recurrence, progression, or metastasis of the cancer or precursor hyperplasia or neoplasia thereof, a pharmaceutically acceptable salt comprising one or more cations having the formula:
- R , 1 wherein a) A is an antioxidant moiety comprising one or more nitroxide or hydroxyl amine moieties, or a pro-drug thereof, having from three to 16 carbon atoms, b) L is an organic linking moiety comprising 4 to 30 carbon atoms, c) E is a nitrogen or phosphorus atom, d) R 1 ' , Ri " , and Rj " ' are each independently selected organic moieties comprising between 1 and 12 carbon atoms, wherein E, Ri', Ri", and Ri'" together form a quaternary ammonium or phosphonium cation; and wherein the salt further comprises one or more X m" pharmaceutically acceptable anions, where m is an integer from 1 to 4, in sufficient quantities to form the pharmaceutically acceptable salt.
- a related aspect of the disclosure relates to a method for treating, regulating or inhibiting the prostate's inflammation, hyperplasia or enlargement and the occurrence, recurrence, progression or metastasis of prostate cancer, consisting of administering to a mammal diagnosed as having prostate disease or cancer or precursor neoplasia thereof, in an amount effective to treat the cancer or modulate the inflammation, hyperplasia, or enlargement of the prostate or the occurrence, recurrence, progression, or metastasis of prostate cancer or precursor neoplasia thereof, with one or more pharmaceutically acceptable salts having one or more cations having the formula
- E is a nitrogen or phosphorus atom
- R f ', Ri", and Rj' are each independently selected organic moieties comprising between 1 and 12 carbon atoms
- n is an integer between 8 and 12
- R s ' , Ri " , and R j " ' are each independently selected organic moieties comprising between 1 and 12 carbon atoms, wherein E, R 1 ', Ri", and Ri'" together form a quaternary ammonium or phosphonium cation
- the salt further comprises one or more pharmaceutically acceptable anions X m" , wherein m is an integer from 1 to 4, in sufficient amount to form the pharmaceutically acceptable salt.
- E is a nitrogen or phosphorus atom
- R i ' , R i " , and R 1 '" are each independently selected organic moieties comprising between 1 and 12 carbon atoms
- n is an integer between 5 and 12
- E, Ri', R 1 ", and R 1 '" together form a quaternary ammonium or phosphonium cation
- the salt forther comprises is one or more pharmaceutically acceptable anions X m ⁇ , wherein m is an integer from 1 to 4, in sufficient amount to form the pharmaceutically acceptable salt.
- Another aspect of the disclosure relates to salts comprising one or more cations having the formula:
- E is a nitrogen or phosphorus atom
- R] ', Ri ", and Ri '" are each independently selected organic moieties comprising between 1 and 12 carbon atoms
- n is an integer between 5 and 12
- E, Ri', Rj", and Rj '" together form a quaternary ammonium or phosphonium cation
- the salt further comprises one or more anions X m' in a sufficient amount to form the pharmaceutically acceptable salt.
- Figure 1 shows the inhibitory effect of varying concentrations of MitoT on the proliferation and growth of human prostate tumor LNCaP and PC-3 cells, as determined by Hoechst dye-DNA fluorescence assays.
- Figure 2 shows a microscopic picture of DCF fluorescence (green) and Hoechst dye-
- Figure 3 shows the inhibitory effect of treatment with varying concentrations of MitoT on the oxidative stress levels in LNCaP human prostate tumor cells, as determined by the ratio of DCF fiuorescence/Hoechst dye-DNA fluorescence.
- FIG. 4 shows that MitoT treatment at sufficient concentrations reduces the ROS level and causes inhibition of cell growth and proliferation in LNCaP human prostate cancer cells
- A Plot of % control of MTT absorbance at increasing MitoT concentration shows MitoT absorbs mitochondrial electrons.
- B Plot of the ratio of % of control cell MTT absorbance/DNA fluorescence shows that the decrease in MTT oxidation is related to cell growth arrest.
- Figure 5 shows that synthetic androgen (Rl 881) treatment-induced oxidative stress in LNCaP human prostate cancer cells, as determined by the ratio of DCF fluorescence/DNA fluorescence, is strongly inhibited by pre-treatment of the ceils with 1 ⁇ M MitoT.
- Figure 6 shows the pharmacokinetics of MitoT absorption in serum and in kidney tissues of white mice given one intraperitoneal (i.p.) injection of MitoT (5 mg/kg) showing serum clearance and tissue accumulation of the drug with the passage of time.
- Figure 7 shows pictorial microscopic evidence of Hydroethidine dye fluorescence due to ROS oxidation in kidney tissue of (A) untreated mice and (B) mice treated with 5 mg/kg MitoT for 3 hours.
- Figure 8 shows the inhibitory effect of varying concentrations of MitoT- 10 on the growth and proliferation of LNCaP and PC-3 human prostate cancer cells, as determined by Hoechst dye-DNA fluorescence assays
- ranges are expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about,” it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.
- a cell can be in vitro. Alternatively, a cell can be in vivo and can be found in a subject.
- a "cell” can be a cell from any organism including, but not limited to, a bacterium or a mammalian cell or a tumor cell.
- a “subject” is meant an individual.
- the "subject” can include domesticated animals, such as cats, dogs, etc., livestock (e.g., cattle, horses, pigs, sheep, goats, rabbits, etc.), laboratory animals (e.g., mouse, rabbit, rat, guinea pig, ferret, mink, etc.) and birds.
- livestock e.g., cattle, horses, pigs, sheep, goats, rabbits, etc.
- laboratory animals e.g., mouse, rabbit, rat, guinea pig, ferret, mink, etc.
- the subject is a higher mammal such as a primate or a human.
- the compounds described herein can be administered to a subject comprising a human or an animal including, but not limited to, a murine, canine, feline, equine, bovine, porcine, caprine or ovine species and the like, that is in need of alleviation or amelioration from a recognized medical condition.
- references in the specification and concluding claims to parts by weight, of a particular element or component in a composition or article denotes the weight relationship between the element or component and any other elements or components in the composition or article for which a part by weight is expressed.
- X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.
- a weight percent of a component is based on the total weight of the formulation or composition in which the component is included.
- moiety defines a carbon containing residue, i.e. a moiety comprising at least one carbon atom, and includes but is not limited to the carbon-containing groups defined hereinabove.
- Organic moieties can contain various heteroatoms, or be bonded to another molecule through a heteroatom, including oxygen, nitrogen, sulfur, phosphorus, or the like. Examples of organic moieties include but are not limited alkyl or substituted alkyl s, alkoxy or substituted alkoxy, mono or di-substituted amino, amide groups, etc.
- Organic moieties can preferably comprise 1 to 21 carbon atoms, 1 to 18 carbon atoms, 1 to 15, carbon atoms, 1 to 12 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms.
- alkyl denotes a moiety containing a saturated, straight or branched hydrocarbon residue having from 1 to 18 carbons, or preferably 4 to 14 carbons, 5 to 13 carbons, or 6 to 10 carbons.
- An alkyl is structurally similar to a non-cyclic alkane compound modified by the removal of one hydrogen from the non-cyclic alkane and the substitution, therefore, with a non-hydrogen group or moiety.
- Alkyl moieties can be branched or unbranched. Lower alkyl moieties have 1 to 4 carbon atoms.
- alkyl moieties include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, t-butyl, amyl, t-amyl, n-pentyl and the like.
- substituted alkyl denotes an alkyl moiety analogous to the above definition that is substituted with one or more organic or inorganic substituent moieties. In some embodiments, 1 or 2 organic or inorganic substituent moieties are employed. In some embodiments, each organic substituent moiety comprises between 1 and 4, or between 5 and 8 carbon atoms.
- Suitable organic and inorganic substituent moieties include, but are not limited to, hydroxyl, halogens, cycloalkyl, amino, mono -substituted amino, di-substituted amino, acyloxy, nitro, cyano, carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide, alkylsulfonyl, alkylsulfinyl, thioalkyl, thiohaloalkyl, alkoxy, substituted alkoxy, haloalkyl, haloalkoxy, heteroaryl, substituted heteroaryl, aryl or substituted aryl.
- alkoxy denotes a moiety alkyl, defined above, attached directly to a oxygen to form an ether residue. Examples include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, t-butoxy, iso-butoxy and the like.
- substituted alkoxy denotes a alkoxy moiety of the above definition that is substituted with one or more groups, but preferably one or two substituent groups including hydroxyl, cycloalkyl, amino, mono -substituted amino, di-substituted amino, acyloxy, nitro, cyano, carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide, alkylsulfonyl, alkylsulfinyl, thioalkyl, thiohaloalkyl, alkoxy, substituted alkoxy or haloalkoxy. When more than one group is present then they can be the same or different.
- mono-substituted amino denotes an amino (-NH 2 ) group substituted with one group selected from alkyl, substituted alkyl or arylalkyl wherein the terms have the same definitions found throughout.
- di-substituted amino denotes an amino substituted with two moieties that can be same or different selected from aryl, substituted aryl, alkyl, substituted alkyl or arylalkyl wherein the terms have the same definitions found throughout. Some examples include dimethylamino, methylethylamino, diethylamino and the like.
- haloalkyl denotes a alkyl moiety, defined above, substituted with one or more halogens, preferably fluorine, such as a trifluoromethyl, pentafluoroethyl and the like.
- haloalkoxy denotes a haloalkyl, as defined above, that is directly attached to an oxygen to form a halogenated ether residue, including trifluoromethoxy, pentafluoroethoxy and the like.
- Acyl moieties contain 1 to 8 or 1 to 4 carbon atoms. Examples of acyl moieties include but are not limited to formyl, acetyl, propionyl, butanoyl, iso-butanoyl, pentanoyl, hexanoyl, heptanoyl, benzoyl and like moieties.
- acyloxy denotes a moiety containing 1 to 8 carbons of an acyl group defined above directly attached to an oxygen such as acetyloxy, propionyloxy, butanoyloxy, iso -butanoyloxy, benzoyloxy and the like.
- aryl denotes an unsaturated and conjugated aromatic ring moiety containing 6 to 18 ring carbons, or preferably 6 to 12 ring carbons. Many aryl moieties have at least one six-membered aromatic "benzene” moiety therein. Examples of such aryl moieties include phenyl and naphthyl.
- substituted aryl denotes an aryl ring moiety as defined above that is substituted with or fused to one or more organic or inorganic substituent moieties, which include but are not limited to a halogen, alkyl, substituted alkyl, haloalky, hydroxyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, amino, mono- substituted amino, di-substituted amino, acyloxy, nitro, cyano, carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide, alkylsulfonyl, alkylsulfinyl, thioalkyl, thiohaloalkyl, alkoxy, substituted alkoxy or haloalkoxy, aryl, substituted aryl, heteroaryl, heterocycl
- Substituted aryl moieties can have one, two, three, four, five, or more substituent moieties.
- the substituent moieties can be not be of unlimited size or molecular weight, and each organic moiety can comprise 15 or fewer, 10 or fewer, or 4 or fewer carbon atoms unless otherwise expressly contemplated by the claims
- heteroaryl denotes an aryl ring moiety as defined above, wherein at least one of the carbons of the aromatic ring has been replaced with a heteroatom, which include but are not limited to nitrogen, oxygen, and sulfur atoms.
- Heteroaryl moieties include 6 membered aromatic ring moieties, and can also comprise 5 or 7 membered aromatic rings, or bicyclic or polycycMc heteroaromatic rings as well. Examples of heteroaryl moieties include pyridyl, bipyridyl, furanyl, and thiofuranyl residues.
- heteroaryl moieties can optionally be substituted with one or more organic or inorganic substituent moieties bound to the carbon atoms of the heteroaromatic rings, as described hereinabove for substituted aryl moieties.
- Substituted heteroaryl moieties can have one, two, three, four, five, or more substituent organic or inorganic moieties, in a manner analogous to the substituted aryl moieties defined herein.
- the substituent moieties cannot be of unlimited size or molecular weight, and each organic substituent moiety can comprise 15 or fewer, 10 or fewer, or four or fewer carbon atoms unless otherwise expressly contemplated by the claims.
- halo refers to a fluoro, chloro, bromo or iodo atom or ion.
- heterocycle refers to a moiety having a closed ring structure comprising 3 to 10 ring atoms, in which at least one of the atoms in the ring is an element other than carbon, such as, for example, nitrogen, sulfur, oxygen, silicon, phosphorus, or the like.
- Heterocyclic compounds having rings with 5, 6, or 7 members are common, and the ring can be saturated, or partially or completely unsaturated.
- the heterocyclic compound can be monocyclic, bicyclic, or polycyclic. Examples of heterocyclic compounds include but are not limited to pyridine, piperidine, thiophene, furan, tetrahydrofuran, and the like.
- substituted heterocyclic refers to a heterocyclic moiety as defined above having one or more organic or inorganic substituent moieties bonded to one of the ring atoms.
- carboxy refers to the - C(O)OH moiety that is characteristic of carboxylic acids.
- the hydrogen of the carboxy moieties is often acidic and (depending on the pH) often partially or completely dissociates, to form an acid H+ ion and a carboxylate anion (-CO 2 " ), wherein the carboxylate anion is also sometimes referred to as a "carboxy" moiety.
- a chiral atom is present in a compound disclosed herein, both separated enantiomers, racemic mixtures and mixtures of enantiomeric excess are within the scope of the invention. Separation of such mixtires may be done using techniques known in the art.
- a racemic mixture is an equal ratio of each of the enantiomers, whereas an enantiomeric excess is when the percent of one enantiomer is greater than the other enantiomer, all percentages are within the scope of the invention. Furthermore, when more than one chiral atom is present in a compound, then the enantiomers, racemic mixtures, mixtures of enantiomeric excess and diastereomic mixtures are within the scope of the invention.
- the salts comprise a mixture of cations and anions whose total number of positive and negative charges are electrically balanced. More particularly, however, the salts disclosed herein have one or more cations having the Formula (I) illustrated below ⁇
- A is an antioxidant moiety comprising one or more nitroxide or hydroxylamine moieties, or a prodrug thereof
- L is an organic linking moiety
- E is a nitrogen or phosphorus atom
- Rj ', Ri ", and R 5 '" are each independently selected from organic moieties comprising between 1 and 12 carbon atoms, wherein E, Ri', Ri", and R 1 '" together form a quaternary ammonium or phosphonium cation
- the salt further comprises is one or more pharmaceutically acceptable anions X m" , wherein m is an integer from 1 to 4, in sufficient amount to form the pharmaceutically acceptable salt.
- the various genera, subgenera, and species of the compounds of Formula (I) share at least the features disclosed above, and have related functions and utilities, but can differ in specific structural features, as described below.
- the compounds of the invention all comprise at least one antioxidant moiety "A" which comprises at least one or more nitroxide radial or hydroxyl amine moieties bonded therein or thereto.
- Nitroxides and relevant hydroxylamines have the chemical structures shown below:
- the "A" moieties of the salts described herein which comprise one or more nitroxide orhydroxyl amine moieties, can catalyze the dismutation of superoxide radical anions in the cell, to form hydrogen peroxide which can be dealt with by enzymes in the cell, and therefore serve to function as "anti-oxidants.”
- the nitroxide or hydroxylamine moieties are part of a larger A moiety, which in many embodiments can comprise between 4 and 30 carbon atoms, or, 6 to 24 carbon atoms, or 7 to 18 carbon atoms, or from 8 to 12 carbon atoms.
- the A moieties have 5 or 6-member rings containing a nitroxide free radical therein having the formulas:
- R moieties are organic substitutent moieties.
- the R moieties can be C, -C 4 alkyls, aryls, alkoxides, and the like.
- the R moieties can be C 1 -C 4 linear or branched alkyl, for example, methyl (C 1 ), ethyl (C 2 ), n-propyl
- R 2 moieties are all methyl groups as shown below, which are [2,2,5,5-tetramethylpyrrolidinyloxy] free radical having the formula:
- the "A" moieties are [2,2,6,6-tetramethylpiperidinyloxy] free radical moieties the formula:
- L g can be any of a variety of moieties that form a bond to the "L" linking group.
- the L g moieties taken together with nitroxide free radical moieties can provide "Tempol" analog moieties having the formula:
- the L g moieties taken together with nitroxide free radical moieties can provide "Proxyl" analog moieties having the formula:
- L moieties serve to connect the quaternary ammonium and/or phosphonium salt moieties with the A moieties.
- L moieties can comprise a polyalkylene chain having 5 to 30 carbon chain atoms, wherein any one or more of the hydrogens bonded to said carbon chain atoms can be optionally substituted with one or two independently selected hydroxyl, halogen, amino, methylamino, dimethylamino, or C]-C 4 organic moieties selected from alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties.
- the compounds useful for the methods of the disclosure comprise one or more cationic moieties.
- the cationic moieties carry a positive charge, which, while not being bound by theory, is believed to cause the desirable selective accumulation of the resultant compounds in the mitochondria, because of the large mitochondrial membrane potential of 150- 170 mV, and the resulting electrostatic attractions.
- the selective accumulation of the cationic salts disclosed herein is also improved if the cationic moieties comprise relatively large and/or lipophilic organic substitutent moieties, so that the resulting cationic group is relatively lipophilic when considered as a whole.
- Ri', Ri", and Rj'" are each independently organic moieties comprising from 1 to 32 carbon atoms.
- the compounds of Formula (I) can have R b , R 1 ", and R 1 "' are each independently selected from alkyl, aryl, heteroaryl, or aralkyl moieties, which may be unsubstituted, or optionally substituted with one or two independently selected substituent moieties, such as those described above, which include but are not limited to hydroxyl, halogen, amino, amino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties.
- Non-limiting examples of the optional substituents for R 1 ', R 1 ", and R 1 '” include: i) CrC 4 linear branched alkyl; for example, methyl (Cj), ethyl (C 2 ), n-propyl
- Ci-C 4 linear or branched alkoxy for example, methoxy (Ci), ethoxy (C 2 ), n- propoxy (C 3 ), wo-propoxy (C 3 ), n-butoxy (C 4 ), sec-butoxy (C 4 ), iso-bntoxy (C 4 ), and tert-butoxy (C 4 ) ; iii) halogen; for example, -F, -Cl, -Br, -I, and mixtures thereof; iv) amino and substituted amino; for example, -NH 2 , -NH 2 , -NHCH 3 , -NHCH 3 , and -N(CH 3 ) 2 ; v) hydroxyl; -OH; vi) Ci-C 4 linear or branched hydroxyalkyl; for example, -CH 2 OH, -CH 2 CH 2 OH,
- Ci-C 4 linear or branched alkoxyalkyl for example, -CHiOCH 3 , -CH 2 CH 2 OCH 3 , -CH 2 CH 2 CH 2 OCH 3 , and -CH 2 CH(OCH 3 )CH 3 ; viii) carboxy or carboxylate, for example, -CO 2 H or the anionic equivalent carboxylate moieties -CO 2 " ; and xi) carboxyalkyl, for example, -CH 2 CO 2 H, -CH 2 CH 2 CO 2 H, -CH 2 CO 2 CH 3 , -CH 2 CH 2 CO 2 CH 3 , and -CH 2 CH 2 CH 2 CO 2 CH 3 .
- Ri', Ri", and R 1 '" can be each independently selected from alkyl, aryl, or benzyl moieties optionally substituted with one or two independently selected hydroxyl, halogen, amino, diamino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties.
- R 1 ', R 1 ", and R 1 '" can be independently selected from C4-C 10 alkyl or phenyl moieties, which can optionally be substituted with one or two independently selected substituent moieites, which can include but are not limited to hydroxyl, halogen, amino, diamino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, cyano,carboxy, or carboxyalkyl moieties.
- R 1 ', R ! ", and R 1 '" can be independently selected from C4-C1 0 alkyl or phenyl moieties.
- R 1 ', R 1 ", and R 1 '" are independently selected from C 4 -C 10 alkyl. In yet other related embodiments R 1 ', R 1 ", and R 1 '" are each n-C 4 H 9 moieties.
- R 1 ', R 1 ", and R 1 '" are each phenyl moieties, to produce triphenyl phosphonium cations having the formula:
- R 1 ', R 1 ", and R 1 '" are each benzyl moieties, to produce tribenzyl phosphonium cations having the formula:
- R 1 ', R 1 ", and R 1 '" are each independently selected from alkyl, aryl, heteroaryl, or aralkyl moieties, which can be optionally substituted with one or two independently selected substituent moieties, which include but are not limited to hydroxyl, halogen, amino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, cyano, carboxy, or carboxyalkyl moieties.
- substituent moieties include but are not limited to hydroxyl, halogen, amino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, cyano, carboxy, or carboxyalkyl moieties.
- Non-limiting examples of the R 1 ', R ! ", and R 1 '" substituents include: i) C]-C 4 linear branched alkyl; for example, methyl (CO, ethyl (C 2 ),
- C 3 wo- ⁇ ropyl (C 3 ), n-butyl (C 4 ), sec-butyl (C 4 ), iso-bntyl (C4), and tert-butyl (C 4 ); ⁇ ) C 1 -C 4 linear or branched alkoxy; for example, methoxy (Cj), ethoxy (C 2 ), n- propoxy (C 3 ), /so-propoxy (C 3 ), n-butoxy (C 4 ), sec-butoxy (C 4 ), ir ⁇ -butoxy iii) halogen; for example, -F, -Cl, -Br, -I, and mixtures thereof; iv) amino and substituted amino; for example, -NH 2 , -NH 2 , -NHCH 3 , -NHCH 3 , and -N(CH 3 ) 2 ; v) hydroxyl; -OH; vi) Ci-C 4 linear or branched alk
- R]', Ri", and Ri' are each independently selected from alkyl aryl, or benzyl moieties, which can be optionally substituted with one or two independently chosen substitutent moieties, such as those described above, which include but are not limited hydroxyl, halogen, amino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties.
- R 1 ', R 1 ", and R 1 "' are independently selected from C 4 -Cj O alkyl or phenyl moieties optionally substituted with one or two independently selected hydroxyl, halogen, amino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties.
- R 1 ', R 1 ", and R 1 '" are independently selected from C 4 -C JO alkyl or phenyl moieties; and in one further embodiment R 1 ', R 1 ", and R 1 '" are independently selected from C 4 -CiO alkyl.
- R I ? , R 1 ", and R 1 '" are each n-C 4 Hg moieties.
- the "L” Linker Moiety The cations of Formula (I) comprise a linker moiety "L", which connects the "A" moiety and the cationic moiety.
- the exact structure and size of the L moieties can vary considerably, and many variations of the L moieties are within the scope of the inventions disclosed herein. In some the L moieties are often organic moieties, and can comprise a wide variety of structures. In many embodiments it is desirable that the L moiety be of sufficient size and character that it provides some space and/or flexibility in the connection between the A and cation groups, but does not become of such high molecular weight so as to impair the water solubility or trans-membrane absorbability of the resulting cations.
- the L moiety when considered as a whole, comprises from about 4 and 30 carbon atoms, or from about 4 and 20 carbon atoms. In some embodiments, the L moiety comprises from 6 to 18 carbon atoms, or from 8 to 12 carbon atoms. In some embodiments, the L moieties can comprise only methylene or polymethylene moieties, i.e. -(CHa) n - moieties. Some embodiments provide L having from 5 to 24 carbon chain atoms, for example, -(CHa) n -, wherein the index n is from 5 to 24.
- Another embodiment relates to L having from 5 to 20 carbon chain atoms, for example, -(CH 2 )H-, wherein the index n is from 5 to 20.
- a further embodiment relates to L having from 6 to 16 carbon chain atoms, for example, -(CH 2 ) J1 -, wherein the index n is from 6 to 16.
- a yet further embodiment relates to L having from 7 to 16 carbon chain atoms, for example, - (CH 2 ) n -, wherein the index n is from 7 to 16.
- a still yet further embodiment relates to L having from 8 to 12 carbon chain atoms, for example, -(CHa) n -, wherein the index n is from 8 to 12.
- the L moieties can further comprise in the carbon chain from 1 to 10 additional atoms or groups independently selected from -O-, -S-, -S(O)-, -S(O) 2 -NH-, - NCH 3 -, -C(O)-, or -CO 2 - moieties.
- L can be a polyalkylene glycol moiety, or a polyethylene glycol moiety, having the structure
- n is an integer from 0 to 3.
- the L moiety can comprise therein or thereon an additional ionic substituent moiety, so the electrical charge of the cation of Formula (1) could be increased or decreased.
- the L moiety can comprise an additional one or two quartemary ammonium or phosphonium moiety therein, so that the overall electrical charge of the cation of Formula I could be 2+ or 3+, so as to be a dication, or trication.
- Such dicationic or tricationic compounds can provide even higher water solubility and/or selectivity of absorption into mitochondria than compounds of Formula (I) that are only monocationic.
- the salt compounds comprising the cations of Formula(I) also comprise an anion X m , wherein m is an integer from 1 to 4, corresponding to monoanions, di-anions, tri-anions, and tetra-anions.
- the first iteration of X ' relates to inorganic anion moieties.
- Mono -anionic inorganic anions include any halide anion, such as fluoride, chloride, bromide, or iodide; nitrate, hydrogen sulfate; dihydrogen phosphate, and the like.
- Dianionic inorganic cations can include carbonate, sulfate or hydrogenphosphate, and tri-anionic inorganic anions include phosphates.
- the anions are organic anions.
- organic anion moieties that can be employed to form the salts from the cations of Formula (I) include organosulphates such as methylsulphonate (mesylate), trifluoromethylsulfonate (inflate), benzenesulphonate, toluenesulphonate (tosylate), or purely organic anions, often formed by the neutralization of organic acids, such as fumarate, maleate, maltolate, succinate, acetate, benzoate, oxalate, citrate, or tartrate anions.
- organosulphates such as methylsulphonate (mesylate), trifluoromethylsulfonate (inflate), benzenesulphonate, toluenesulphonate (tosylate), or purely organic anions, often formed by the neutralization of organic acids, such as fumarate, maleate, maltolate, succinate, acetate, benzoate, oxalate
- Step (a) encompasses removal of an H + cation from the starting material with a strong base, with generation of the corresponding 4-alkoxy anion.
- the proton can be removed by any strong organic or inorganic base which is convenient and which does not affect the R substituents.
- organic bases include alkyl or aryl lithium reagents, such as phenyl lithium, methyl lithium, n-butyl lithium, tert-butyl lithium, sodium amide, lithium amide, lithium diisopropylamide, lithium dimethylamide, lithium diethylamide, and the like.
- the formation of the 4-alkoxy anion can be conducted in the cold, i.e. at room temperature or from O 0 C to -78 0 C.
- Non-limiting examples of inorganic bases include NaOH, KOH, LiOH, Ca(OH) 2 , Na 2 CO 3 , K 2 CO 3 , and the like.
- One embodiment which is described herein below utilizes NaH as the base.
- Other hydride bases, inter alia, KH can be utilized especially when low temperature conditions and solvent compatibility cause more reactive bases to be used.
- strong inorganic bases can be used to form organic bases from polar aprotic solvents, inter alia, dimethyl sulfoxide, ⁇ N-dimethylacetamide, and hexamethylphosphoric triamide, for example, a dimsyl anion from dimethyl sulfoxide. Any non-reactive or aprotic solvent or mixtures of solvents can be used for Step (a).
- Non-limiting examples of solvents include alkane solvents, inter alia, pentane, iso-pentane, hexane, heptane, octane, isooctane, and the like; aromatic hydrocarbon solvents, inter alia, benzene, toluene, and xylene (all isomers); ethers, inter alia, diethyl ether, tetrahydro-furan, and dioxane; and various fluorinated hydrocarbons.
- polar aprotic solvents can be used, inter alia, dimethyl sulfoxide, dimethylformamide, AyV-dimethylacetamide, and hexamethylphosphoric triamide.
- a second co-solvent may be used which enhances the solubility of the reagents used in Step (b) without affecting the formation of the anion.
- Step (b) encompasses attaching a linker group L to the alkoxide generated in Step (a).
- the 4-alkoxide is reacted with a linker molecule L having two reactive leaving groups; Z and X.
- the leaving groups may be the same or different.
- L is a linking group comprising from 4 to 30 carbon atoms as described herein.
- Z and X can be any suitable leaving group which is sufficiently reactive to allow attachment of the tether without loss of the free radical moiety.
- suitable leaving groups include halogens: iodine, bromine, and chlorine; sulphonyl leaving groups, inter alia, methylsulphonyl (mesyl), ethylsulphonyl, benzenesulphonyl, toluenesulphonyl (tosyl), and the like.
- Non-limiting examples of compounds having two leaving groups that can be used to as reagents in forming the linking group between the free radical portion of the molecule and the quaternary ammonium or phosphonium moiety include: i) ⁇ , ⁇ -di-bromoalkanes, inter alia, 1 ,4-dibromobutane, 1,5-dibromopentane, 1,6- dibromohexane, 1 ,7-dibromoheptane, 1 ,8-dibromooctane, 1,9-di- bromononane, and 1,10-dibromodecane; ii) ⁇ , ⁇ -di-chloroalkanes, inter alia, 1,4-dichlorobutane, 1 ,5-dichloropentane, 1,6- dichlorohexane, 1,7-dichloroheptane, 1,8-dichlorooctane, 1 ,
- the formulator can take advantage of the differential reactivity of leaving groups when using ⁇ , ⁇ -mixed leaving group alkanes for the formation of the tether. However, the formulator may wish to insert an optional Step (b)(ii) into the process for preparing the compounds of the present invention. For example, the formulator can, once intermediate B is formed, increase the reactivity of leaving group X in order to adjust for any lesser reactivity that the reagent which introduces the quaternary ammonium or phosphonium salt has.
- step l-iodo-4-chlorobutane is used to attach the first end of the tether to the free radical containing unit taking advantage of the increased reactivity of iodine as a preferred leaving group over chlorine. wherein chlorine is replaced by iodine.
- Non-limiting examples of solvents which can be used for Step (b), as well as any optional steps, inter alia, Step (b)(i), include alkane solvents, inter alia, pentane, iso-pentane, hexane, heptane, octane, isooctane, and the like; aromatic hydrocarbon solvents, inter alia, benzene, toluene, and xylene (all isomers); ethers, inter alia, diethyl ether, tetrahydro-furan, and dioxane; and various fluorinated hydrocarbons.
- polar aprotic solvents can be used, inter alia, dimethyl sulfoxide, dimethylformamide, ⁇ yV-dimethylacetamide, and hexamethylphosphoric triamide.
- Step (c) encompasses forming a quaternary ammonium or phosphonium salt at the end of the linking unit opposite the end which contains the nitroxide or amine oxide moiety.
- a quaternary ammonium or phosphonium salt for example, formation of a phosphonium salt:
- Step (c) may optionally be divided into two separate steps, Step (c)(i) and Step (c)(ii), which can be conducted either without isolation of the intermediate C or which can be conducted as two discrete steps, wherein intermediate C is isolated prior to quatemization, for example:
- the formulator can chose the leaving group X which comprises the alkylating agent in Step (c)(ii) to be the same as the leaving group that is displaced in Step (c)(i) or to take the opportunity to provide a different leaving group which results in the potential source of a different counter ion for the quaternary ammonium ion.
- the formulator can alternatively choose to provide the final anion by exchanging the anion present as a result of the reaction which occurs in Step (c) with another anion, and this can be done by exposing the final product to a counter ion exchange system, for example, an ion exchange resin.
- a tri-substituted phosphine can be directly reacted with compounds such as intermediate B to form final compounds. Examples of this reaction are found in Examples 1 and 2 herein below.
- this phosphonium forming step encompasses the reaction taking place in a refluxing solvent. Because a salt if formed, it is advantageous for the formulator to select a solvent wherein the starting materials have good solubility, but the product which forms is either insoluble or has a reduced solubility. In this way when a stoichiometric excess of one starting reagent is used, the excess will potentially remain in solution while the desired product precipitates as an insoluble material.
- Step (c) can be conducted in any non-micleophilic solvent which allows for the adequate formation of the desired product.
- Suitable solvents or mixtures of solvents can be used for Step (c).
- Non-limiting examples of solvents include alkane solvents, inter alia, pentane, iso-pentane, hexane, heptane, octane, isooctane, and the like; aromatic hydrocarbon solvents, inter alia, benzene, toluene, and xylene (all isomers); ethers, inter alia, diethyl ether, tetrahydro-furan, and dioxane; ketones, inter alia, acetone, methyl ethyl ketone, 3-pentanone; halogenated solvents, inter alia, dichloromethane, chloroform, carbon tetrachloride, 1 , 1 -dichloroethane, 1 ,2- dichloro
- reactivity may be increased by the addition of a protic solvent, inter alia, water, methanol, ethanol, and the like, which can aid in solvation and separation of ion pairs, however, these adjustments to Step (c) are within the scope of the artisan and can be made without undue experimentation.
- a protic solvent inter alia, water, methanol, ethanol, and the like, which can aid in solvation and separation of ion pairs, however, these adjustments to Step (c) are within the scope of the artisan and can be made without undue experimentation.
- Scheme II outlines the preparation of a compound disclosed herein which is further described in detail in Example 1.
- Reagents and conditions (a) NaH, benzene; reflux, 24 hr.
- bromide (2) also known as MitoT-10, or CPC-410
- Tempo 1 (0.01 mol) was added to a three-neck flask containing 100 ml dry benzene that is maintained at nitrogen atmosphere.
- sodium hydride (0.015 mol) was added and kept refluxed for 24 hrs.
- the flask was cooled in ice bath and added 1,10- dibromodecane (0.02 mol) in one portion. The refluxing was then resumed for another 72 hrs.
- the contents of the flask was cooled in ice bath and added 25ml water and transferred to a separatory funnel.
- the red upper benzene layer was separated , dried over anhydrous magnesium sulfate and solvent removed by rotory evaporation to get a red oil.
- the oil was purified by column chromatography on silica gel 60.
- the material was added to the column and eluted first with about 150 ml hexane that removed the excess of dibromodecane.
- the desired bromodecanoyl ether of Tempol was eluted with a mixture of hexane and ether
- Scheme IV outlines an example of the preparation of compounds disclosed herein wherein the linking unit is tethered to the free radical portion of the final compound by way of an ester linkage.
- reaction vessel The contents of the reaction vessel were transferred to a separatory funnel and extracted with water (50 mL), brine (50 mL), then dried over Na 2 SO 4 . The solvent was removed in vacuo to afford the desired product which can be used for the next step without further purification.
- Reagents and conditions (a) NaI, acetone; reflux, 24 hr.
- Reagents and conditions (b) triethylamine, dioxane; reflux.
- reaction is cooled to room temperature after which the reaction is poured into diethyl ether (200 mL). The resulting solution is stirred and the organic layer decanted. The solid that remains is triturated with diethyl ether, the solid collected and dried to afford the desired compound.
- Step (d) encompasses attaching a tether to the free radical containing portion of the molecule.
- the 4-amino-2,2, ⁇ , ⁇ -tetraalkylpiperidinyloxy free radical is reacted with a molecule having two reactive leaving groups; Z and X.
- the leaving groups may be the same or different, however, Z is the group which reacts first to form the 4-acyloxy-2, 2,6,6- tetraalkyl-piperidinyloxy free radical intermediate, D, as depicted in Step (d) of Scheme VI.
- Step (e) described herein a quaternary ammonium salt or phosphonium salt is formed, it is convenient for the formulator to utilize as a leaving group X, a unit that can form a stable anion and therefore act as the counter ion for the quaternary ammonium or phosphonium salt that is formed.
- L is a linking group comprising from 4 to 30 carbon atoms as described elsewhere herein
- Scheme VII outlines an example of the preparation of amide compounds disclosed herein wherein the linking unit is tethered to the free radical portion of the final compound by way of an amide linkage. These compounds can be prepared by the following procedure outlined herein below.
- Reagents and conditions (a) 4-bromobutyryl chloride, CH 2 Cl 2 ; rt, 48-72 hr.
- Scheme VIII outlines an example of the preparation of compounds disclosed herein wherein the free radical moiety is derived from a 5-member ring starting material.
- Reagents and conditions (a) 4-bromobutyryl chloride, CH 2 Cl 2 ; rt, 48-72 hr.
- reaction vessel After the addition is complete, the solution is allowed to warm to room temperature and stir over night. The contents of the reaction vessel is transferred to a separatory funnel and extracted with water (50 mL), brine (50 mL), then dried over Na 2 SO 4 . The solvent is removed in vacuo to afford the desired product which can be used for the next step without further purification.
- reaction solution is cooled and the solvent removed under reduced pressure.
- the residue is treated with diethyl ether (200 mL), the organic layer is decanted and the residue dissolved in CH 2 Cl 2 (10 mL) then added to a flask containing diethyl ether (100 mL).
- the precipitate is collect, dissolved in CH 2 Cl 2 and re-precipitated with diethyl ether. This procedure is repeated 3 additional times to afford the desired product.
- the salts described above have been found to be potent compounds in a number of in vitro biological assays that correlate to or are representative of human diseases, especially diseases of uncontrolled inflammation and/or cellular proliferation, including various cancers.
- the biological activity of the compounds described herein can be measured, screened, and/or optimized by testing the salts for their relative ability to kill or inhibit the growth of various human tumor cell lines and primary tumor cell cultures.
- Tumor cell lines that can be employed for such tests include, but are not limited to, known cell lines that model cancers and/or diseases of uncontrolled cellular proliferation, such as: • For Leukemia: CCRF-CEM, HL-60 (TB), K-562, MOLT-4, RPMI-8226, and SR.
- Lung Cancer A549/ATCC, EKVX, HOP-62, HOP-92, NCI-H226, NCI-H23, NCI-H322M, NCI-H460, and NCI-H522.
- Colon Cancer COLO 205, HCC-2998, HCT-1 16, HCT-15, HT-29, KM-12, and SW- 620.
- CNS Cancer SF-268, SF-295, SF-539, SNB- 19, SNB-75, U-231 , U-235 and U-251.
- Renal Cancer 786-0, A-498, ACHN, CAKI-I, RXF-393, RXF-631, SN12C, TK-IO, and UO-31.
- Prostate Cancer DU-145, PC-3 and LNCaP. • Breast Cancer: MDA-MB-468, MCF 7, MCF7/ADR-RES, MDA-MB-231/ATCC,
- Pancreatic Cancer PANC-I , Bx-PC3 AsPC-I .
- the anti-cancer effectiveness can be gauged using a variety of assay procedures known to those of ordinary skill in the art for measuring the number of live cells in the cultures as a function of time.
- MTT 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide
- MTT assay procedures have an advantage over an in vivo assay with common laboratory animals such as mice, in that results are obtained within a week as opposed to requiring several weeks or months.
- MTT anti-cancer activity screening assay provides data regarding the general cytotoxicity of an individual compound.
- active anticancer compounds can be identified by applying the compounds at a concentration of about 10 ⁇ M to one or more cultured human tumor cell lines, such as for example leukemia, lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, or pancreatic cancer, so as to kill or inhibit cell growth of the tumor cells.
- the compounds of the invention are considered to be biologically active for the treatment of a particular cancer if, when they are applied to a culture of one of the above cancer cell lines at a concentration of about 10 ⁇ M or less, for a period of at least about 5 days, the growth of the cancer cells is inhibited, or the cancer cells killed to the extent of about 50% or more, as compared to a control not comprising the compound of the invention.
- each culture plate was thawed and equilibrated to room temperature under protection from light. Hoechst dye was then added to each well in 200 ⁇ L of high salt TNE buffer (10 mM Tris, ImM EDTA, 2 M NaCl [pH 7.4]) at a final concentration of 6.7 ⁇ g/mL. After further incubation at room temperature for 2 hours under protection from light, culture plates were scanned on the CytoFluor 2350TM scanner using the 360/460 nm filter excitation and emission set. The DNA fluorescence intensity was used as a measure of cell growth.
- TNE buffer 10 mM Tris, ImM EDTA, 2 M NaCl [pH 7.4]
- Mito-T drug The effects of varying concentrations of Mito-T drug on the growth of LNCaP and PC-3 cells over a period of 4 days was assayed using the Hoechst dye-DNA fluorescence assay described above. In these and all subsequent cell culture studies described below, each data point and its associated error bar are respectively, an average value and the standard deviation of data obtained from six wells of a 96-well plate run in duplicate in three separate sets of experiments.
- Mito-T treatment inhibits the growth of both LNCaP and PC-3 cells, with estimated ICgo values of approximately 4 ⁇ M and 60 ⁇ M, respectively.
- the inhibitory effect of MitoT on the oxidative stress level in LNCaP prostate tumor cells can also be determined by the ratio of DCF fluorescence / Hoechst dye-DNA fluorescence (Ripple MO, Henry WF, Rago RP, Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst. 1997 Jan 1 ;89(l):40-8 .
- DCFH is oxidized to DCF by ROS to yield easily quantifiable ROS levels monitored by the green fluorescence of the DCF (6-carboxy-2 r ,7'-dichlorofiuorescin diacetate) dye, as can be seen in Figure 2.
- the inhibitory effect of MitoT on the oxidative stress level in LNCaP prostate tumor cells can be determined by the ratio of DCF fluorescence/Hoechst dye-DNA fluorescence.
- MitoT treatment markedly reduced the oxidative stress in LNCaP cells as determined by DCF fluorescence/DNA fluorescence assay shown in Figure 3. MitoT treatment effectively and reproducibly reduced the ROS levels in LNCaP cells at concentrations at or above about 1-10 ⁇ M. It should be noted that MitoT treatment induced a reduction of oxidative stress determined by DCF assay and mitochondrial function determined by MTT assay, and is parallel to MitoT's effect in the inhibition of prostate tumor cell growth as determined by DNA assay, as shown in Fig. 4, This oxidative stress is probably due to increased lipid peroxidation during apoptotic and/or necrotic cell death (reviewed in 1,2).
- Figure 6 shows that when animals are treated with MitoT, the serum level of MitoT within the first hour of treatment is between 10-20 ⁇ g/ml, which is 10 - 20 times above the level of MitoT required to block androgen induced oxidative stress in LNCaP cells (Fig. 5) and in the concentration range of completely blocking all oxidative stress in the cancer cells. Also, under these treatment conditions, MitoT markedly reduced the oxidative stress in the prostatic lumen of live animals, as observed by Hydroethidine dye oxidation assay in the animal's prostate. Hydroethidine dye was injected into the tail vein of male mice one hour before sacrifice. Hydroethidine shows a typical red fluorescence upon oxidation by ROS.
- the compounds described herein can be used to prevent, alleviate or otherwise treat diseases of uncontrolled proliferation in mammals, including humans, such as cancer or precancerous diseases.
- the compounds described herein can be used for the preparation of medicaments for treating diseases of uncontrolled inflammation, proliferation, cancers, and prostate cancer.
- the invention relates to methods of treatment for a disease of uncontrolled cellular inflammation, proliferation, wherein the method comprises administering to a mammal diagnosed as having a disease of uncontrolled cellular inflammation and/or proliferation a compound of the invention or a pharmaceutical composition thereof comprising one or more of the compounds of the invention, in an amount that is effective to treat the disease of uncontrolled cellular inflammation and/or proliferation.
- the disease of uncontrolled cellular inflammation and/or proliferation treated can be a hyperplasia or a carcinoma, lymphoma, leukemia, or sarcoma.
- the types of diseases treated by methods of the invention include but are not limited to Hodgkin's Disease, myeloid leukemia, polycystic kidney disease, bladder cancer, brain cancer, head and neck cancer, kidney cancer, lung cancer, myeloma, neuroblastoma, glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, colon cancer, cervical carcinoma, breast cancer, metastases to the brain or bone, epithelial cancer, and leukemia.
- compositions can also be used as regulators in diseases of uncontrolled inflammation and/or proliferation and/or precancerous conditions such as cervical and anal dysplasias, other dysplasias, severe dysplasias, hyperplasias, atypical hyperplasias, and neoplasias.
- the compounds of the invention have been found to particularly effective for the treatment of prostate cancers and related neoplasias, including pancreas adenocarcinomas or prostate adenocarcinomas, and/or inhibiting the growth of prostate hyperplasias (noncancerous) and/or cancers and related neoplasias.
- the inventions described herein relate to methods for treating or inhibiting the recurrence, progression or metastasis, of a cancer or a neoplasia precursor thereof, consisting of administering to a mammal diagnosed as having a cancer or precursor neoplasia thereof, in an amount effective to treat the cancer or inhibit the recurrence, progression, or metastasis of the cancer or precursor neoplasia thereof, one or more pharmaceutically acceptable salts having a cation having the formula
- R 1 ' wherein a) A is an antioxidant moiety comprising one or more nitroxide or hydroxylamine moieties, or a prodrug thereof, having from three to 16 carbon atoms, b) L is an organic linking moiety comprising 4 to 30 carbon atoms, c) E is a nitrogen or phosphorus atom, d) Ri', Ri", and R 1 '" are each independently selected organic moieties comprising between 1 and 12 carbon atoms, wherein E, R s ', Ri", and R 1 '" together form a quaternary ammonium or phosphonium cation ; and wherein the salt farther comprises is one or more pharmaceutically acceptable anions X m ⁇ , wherein m is an integer from 1 to 4, in sufficient amount to form the pharmaceutically acceptable salt.
- the pharmaceutically acceptable salts of the invention have been found to be particularly effective in treating certain forms inflammation, organ enlargement or cancer, including, but not limited to prostate hyperplasia and/or cancer, colorectal cancer, gastric cancer, renal cancer, skin cancer, head and neck cancer, brain cancer, pancreatic cancer, lung cancer, ovarian cancer, uterine cancer, liver cancer, and breast cancer.
- the invention relates to method for treating, or inhibiting inflammation and benign prostatic hyperplasia or the occurrence, recurrence, progression or metastasis of prostate cancer, consisting of administering to a mammal diagnosed as having prostate disease or cancer or hyperplasia or precursor neoplasia thereof, in an amount effective to treat the disease or cancer or inhibit the occurrence, recurrence, progression, or metastasis of the prostate disease or cancer or precursor neoplasia thereof, one or more pharmaceutically acceptable salts of the invention comprising a cation of Formula (I).
- the pharmaceutically acceptable salts have a cation having the formula:
- E is a nitrogen or phosphorus atom
- Ri', Ri", and Ri' are each independently selected organic moieties comprising between 1 and 12 carbon atoms
- g) n is an integer between 8 and 12
- E, Ri ' , Ri " , and Rj " ' together form a quaternary ammonium or phosphonium cation
- the salt also comprises one or more pharmaceutically acceptable anions X m" wherein m is an integer from 1 to 4, sufficient to form the pharmaceutically acceptable salt.
- compositions described herein can be administered as pure chemicals either singularly or p rurally, it is preferable to present the active ingredient as a pharmaceutical composition.
- another embodiment of the invention is the use of a pharmaceutical composition comprising one or more compounds and/or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers thereof and, optionally, other therapeutic and/or prophylactic ingredients.
- the carrier(s) should be "acceptable" in the sense of being compatible with the other ingredients of the composition and not overly deleterious to the recipient thereof.
- pharmaceutical composition is administered to an animal diagnosed as in need of treatment for a disease of uncontrolled cellular inflammation and/or proliferation, in an amount effective to treat the disease of uncontrolled cellular inflammation and/or proliferation, such as the various cancers and precancerous conditions described herein.
- pharmaceutical composition means therapeutically effective amounts of a pharmaceutically effective compound together with suitable combination of one or more pharmaceutically-acceptable carriers, many of which are known in the art, including diluents, preservatives, solubilizers, emulsifiers, and adjuvants, collectively”.
- the terms "effective amount” and “therapeutically effective amount” refer to the quantity of active therapeutic agent sufficient to yield a desired therapeutic response, without undue adverse side effects, such as toxicity, irritation, or allergic response.
- the specific "effective amount” will, obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the type of animal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives. In this case, an amount would be deemed therapeutically effective if it resulted in one or more of the following: (a) the prevention of an androgen-mediated or androgen-independent disorder (e. g.
- prostate cancer prostate cancer
- reversal or stabilization of an androgen-mediated or androgen-independent disorder e. g., prostate disease and cancer.
- the optimum effective amounts can be readily determined by one of ordinary skill in the art using routine experimentation .
- compositions can be liquids or lyophilized or otherwise dried formulations and include diluents of various buffer content (e. g.,Tris-HCI, acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e. g., Tween 20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents (e. g., glycerol, polyethylene glycerol), anti-oxidants (e. g., ascorbic acid, sodium metabisulfite), preservatives (e. g., Thiomersal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.
- buffer content e. g.,Tris-HCI, acetate, phosphate
- pH and ionic strength additives such as albumin or gelatin to prevent absorption to surfaces
- additives e. g., Tween 20, T
- Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
- Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on
- Ringer's dextrose and the like.
- Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, collating agents, inert gases and the like.
- Controlled or sustained release compositions administrable according to the invention include formulation in lipophilic depots (e. g. fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e. g. poloxamers or poloxamines) and the compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to Hgands of tissue-specific receptors.
- lipophilic depots e. fatty acids, waxes, oils.
- particulate compositions coated with polymers e. g. poloxamers or poloxamines
- compositions administered according to the invention incorporate particulate forms, protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral.
- a pharmaceutical composition can be delivered in a controlled release system.
- the agent may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration.
- a pump may be used (see Langer, supra; Sefton, CRC Crit Ref. Biomed. Eng. 14: 201 (1987); Buchwald et al., Surgery 88: 507
- a controlled release system can be placed in proximity to the therapeutic target, i. e., the prostate, thus requiring only a fraction of the systemic dose (see, e. g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984). Other controlled release systems are discussed in the review by Langer (Science 249: 1527-1533 (1990).
- the pharmaceutical preparation can comprise the anti-androgen compound alone, or can further include a pharmaceutically acceptable carrier, and can be in solid or liquid form such as tablets, powders, capsules, pellets, solutions, suspensions, elixirs, emulsions, gels, creams, or suppositories, including rectal and urethral suppositories.
- Pharmaceutically acceptable carriers include gums, starches, sugars, cellulosic materials, and mixtures thereof.
- the pharmaceutical preparation containing the anti-androgen compound can be administered to a patient by, for example, subcutaneous implantation of a pellet.
- a pellet provides for controlled release of anti-androgen compound over a period of time.
- the preparation can also be administered by intravenous, intra-arterial, or intramuscular injection of a liquid preparation oral administration of a liquid or solid preparation, or by topical application. Administration can also be accomplished by use of a rectal suppository or a urethral suppository.
- the active compounds of the invention are administered to achieve peak plasma concentrations of the active compound of from typically about 0.1 to about 100 ⁇ M, about 1 to 50 ⁇ M, or about 2 to about 30 ⁇ M. This can be achieved, for example, by the intravenous injection of a 0.05% to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 0.5-500 mg of the active ingredient. Desirable blood levels can be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the active compounds of the invention.
- compositions include those suitable for oral, enteral, parental (including intramuscular, subcutaneous and intravenous), topical, nasal, vaginal, ophthalin ⁇ cal, sublingual, nasal or by inhalation administration.
- the compositions can, where appropriate, be conveniently presented in discrete unit dosage forms and can be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active compound with liquid carriers, solid matrices, semi-solid carriers, finely divided solid carriers or combination thereof, and then, if necessary, shaping the product into the desired delivery system.
- the compounds of the invention can have oral bioavailability as exhibited by blood levels after oral dosing, either alone or in the presence of an excipient. Oral bioavailability allows oral dosing for use in chronic diseases, with the advantage of self-administration and decreased cost over other means of administration.
- Pharmaceutical compositions suitable for oral administration can be presented as discrete unit dosage forms such as hard or soft gelatin capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or as granules; as a solution, a suspension or as an emulsion.
- the active ingredient can also be presented as a bolus, electuary or paste.
- Tablets and capsules for oral administration can contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents.
- the tablets can be coated according to methods well known in the art., e.g., with enteric coatings.
- Oral liquid preparations can be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or can be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations can contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which can include edible oils), or one or more preservative.
- the pharmaceutical preparations administrable by the invention can be prepared by known dissolving, mixing, granulating, or tablet-forming processes.
- the compounds or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are mixed with additives customary for this purpose, such as vehicles, stabilizers, or inert diluents, and converted by customary methods into suitable forms for administration, such as tablets, coated tablets, hard or soft gelatin capsules, aqueous, alcoholic or oily solutions.
- suitable inert vehicles are conventional tablet bases such as lactose, sucrose, or cornstarch in combination with binders such as acacia, cornstarch, gelatin, with disintegrating agents such as cornstarch, potato starch, alginic acid, or with a lubricant such as stearic acid or magnesium stearate.
- suitable oily vehicles or solvents are vegetable or animal oils such as sunflower oil or fish-liver oil. Preparations can be effected both as dry and as wet granules or supercritically formulated nanoparticles.
- the compounds can also be formulated for parenteral administration (e.g., by injection, for example, bolus injection or continuous infusion) and can be presented in unit dose form in ampules, pre-filled syringes, small bolus infusion containers or in multi-does containers with an added preservative.
- the compositions can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the active ingredient can be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
- the compounds or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are converted into a solution, suspension, or expulsion, if desired with the substances customary and suitable for this purpose, for example, solubilizers or other auxiliaries.
- sterile liquids such as water and oils, with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants.
- Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil.
- water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycols or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions.
- compositions which contain an active component are well understood in the art.
- Such compositions may be prepared as aerosols delivered to the nasopharynx or as injectables, either as liquid solutions or suspensions; however, solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared.
- the preparation can also be emulsified.
- the active therapeutic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like or any combination thereof.
- composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents which enhance the effectiveness of the active ingredient.
- auxiliary substances such as wetting or emulsifying agents, pH buffering agents which enhance the effectiveness of the active ingredient.
- the compounds of the invention comprise cationic anti-oxidants in the form pharmaceutically acceptable salt with pharmaceutically acceptable anions.
- Pharmaceutically acceptable salts include pharmaceutically acceptable halides such as fluoride, chloride, bromide, or iodide, tribasic phosphate, dibasic hydrogen phosphate, monobasic dihydrogen phosphate, or the anionic forms of pharmaceutically acceptable organic carboxylic acids as acetates, oxalates, tatrates, mandelates, succinates, citrates, and the like.
- Such pharmaceutically acceptable salts can be readily synthesizes from other salts used for the initial synthesis of the compounds by ion exchange reactions and technologies well known to those of ordinary skill in the art.
- Salts formed from any free carboxyl groups on the cationic antioxidant moieties can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases asisopropylamine, trimethylamine, 2- ethylamino ethanol, histidine, procaine, and the like.
- inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases asisopropylamine, trimethylamine, 2- ethylamino ethanol, histidine, procaine, and the like.
- the salts of the anti-androgen compound may be pharmaceutically acceptable salts.
- Other salts may, however, be useful in the commercial or laboratory preparation of the compounds according to the invention or of their pharmaceutically acceptable salts.
- Suitable pharmaceutically acceptable salts of the compounds include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
- the salts described herein may be provided in the form of nutraceutical compositions where the anti-oxidant properties of the salts prevents the onset of or reduces or stabilizes various disorders, e.g., including inhibiting the occurrence of various forms of cancer, including prostate cancer.
- the term "nutraceutical,” or “nutraceutical composition,” for the purposes of this specification, refers to a food item, or a part of a food item, that offers medical health benefits, including prevention and/or treatment of disease.
- a nutraceutical composition according to the present invention may contain only a cationic antioxidant compound according to the present invention as an active ingredient or, alternatively, may further comprise, in admixture with the aforesaid cationic antioxidant compound, dietary supplements including vitamins, co-enzymes, minerals, herbs, amino acids and the like which supplement the diet by increasing the total intake of that substance.
- nutraceutical compositions containing a compound having Formula I or a pharmaceutically acceptable salt thereof.
- Such compositions generally include a "nutraceutically-acceptable carrier" which, as referred to herein, is any carrier suitable for oral delivery including, but not limited to, the aforementioned pharmaceutically-acceptable carriers.
- nutraceutical compositions according to the invention comprise dietary supplements which, defined on a functional basis, include immune boosting agents, anti-inflammatory agents, anti-oxidant agents, or mixtures thereof.
- a suitable dose will, in alternative embodiments, typically be in the range of from about 0.5 to about 10 mg/kg/day, or from about 1 to about 20 mg/kg of body weight per day, or from about 5 to about 50 mg/kg/day.
- the desired dose can conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day.
- the sub-dose as necessary by one skilled in the art, can itself be further divided, e.g., into a number of discrete loosely spaced administrations.
- compositions of matter useful for the treatment of cancer and/or benign prostatic hyperplasia contain, in addition to the aforementioned compounds, an additional therapeutic agent.
- agents can be chemotherapeutic agents, ablation or other therapeutic hormones, antineoplastic agents, monoclonal antibodies useful against cancers and angiogenesis inhibitors.
- chemotherapeutic agents can be chemotherapeutic agents, ablation or other therapeutic hormones, antineoplastic agents, monoclonal antibodies useful against cancers and angiogenesis inhibitors.
- DES diethylstilbestrol
- leuprolide flutam ⁇ de
- hydroxyflutamide bicalutamide
- cyproterone acetate ketoconazole
- abiraterone acetate amino glutethimide
- antineoplastic and anticancer agents that can be used in combination with the inventive compounds, 5-fluorouracil, vinblastine sulfate, estramustine phosphate, suramin and strontium-89.
- Other chemotherapeutics useful in combination and within the scope of the present invention are buserelin, chlorotranisene, chromic phosphate, cisplatin, cyclophosphamide, dexamethasone, doxorubicin, estradiol, estradiol valerate, estrogens conjugated and esterified, estrone, ethinyl estradiol, floxuridine, goserelin, hydroxyurea, melphalan, methotrexate, mitomycin and prednisone.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The inventions disclosed include methods of treating cancers and related neoplasias, especially prostate cancer, with pharmaceutically acceptable salts comprising lipophilic cation moieties linked to nitroxide or linked to hydroxylamine anti-oxidant groups, especially derivatives of TEMPO.
Description
MITOCHONDRIA TARGETED CATIONIC ANTI-OXID ANT COMPOUNDS FOR
PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE
DISEASE, NEOPLASIAS AND CANCERS
PRIORITY STATEMENT
This application claims benefit under 35 U.S.C. § 119(e) to U.S. Provisional Application No. 60/905,237, filed March 6, 2007.
STATEMENT REGARDING FEDERALLY FUNDED RESEARCH
Portions of the research and inventions disclosed herein may have been made with U.S. Government support under NIH/NHLBI Grant No. 63119. The U.S. government may have certain rights in this invention.
FIELD OF THE INVENTION
The inventions described herein relate to the treatment of various forms of cancer, or related neoplasias, with compounds that comprise one or more quaternary (check spelling) cationic moieties chemically linked to one or more anti-oxidant moieties comprising nitroxide or amine oxide moieties.
BACKGROUND
Oxidative stress has been known to contribute to a variety of human degenerative diseases associated with aging, such as Parkinson's disease and Alzheimer's disease, as well as to Huntington's Chorea, diabetes and Friedreich's Ataxia (Allen, S., et al., J. Biol. Chem. 278:6371-6383,2003; Hirai, K., et al., J. Neurosci. 21:3017-3023, 2001) and to non-specific cellular damage that accumulates with aging.
Mitochondria are the intracellular organelles primarily responsible for energy metabolism, and are also the major source of the free radicals and reactive oxygen species ("ROS", such as hydrogen peroxide and the superoxide radical anion (O2 ")) that cause oxidative stress and/or damage inside most cells (Murphy MP, Smith RA., Ann. Rev Pharmacol Toxicol. 2006 Oct 2; Epub ahead of print). Mitochondria are equipped to detoxify hydrogen peroxide due to the presence of antioxidant enzymes (peroxiredoxins, thioredoxins, and GSH-dependent peroxidases (Chang, T. S., J. Biol. Chem. 279, 41975-41984, 2004). Typically, mitochondrial superoxide (O 2", the radical anion produced by one electron
reduction OfO2) is dismutated according to the stoichiometry shown below, by manganese superoxide dismutase (MnSOD) that is localized within the mitochondrial matrix.
2O2 " + 2H+ >- O2 + H2O2
However, when cellular ROS production exceeds the cell's detoxification capacity, oxidative damage can occur. This damage disrupts mitochondrial function and oxidative phosphorylation and leads to significant cellular damage to mitochondrial, cytoplasmic or nuclear cellular proteins, DNA, RNA and phospholipids and thus induces cell damage, death and/or disease. Superoxide can also react with nitric oxide at a diffusion-controlled reaction rate, forming a highly potent oxidant and peroxynitrite that can modify proteins and DNA through oxidation and nitration reactions (Beckman, J. S., et al., Nature 364, 584, 1993). In addition to these damaging and pathological roles, ROS also act as a redox signaling molecule(s) and promotes cell proliferation, DNA damage repair errors and mutation leading to inflammatory hyper-proliferation, neoplasia and malignancy (see Michikawa et.al., "Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication." Science. 1999 Oct 22;286(5440):774-9).
Naturally occurring exogenous and endogenous tissue reactive oxygen species (ROS) are known to play a major role in prostate, colorectal, lymphoma and pancreatic carcinogenesis (De Marzo et al,. J Cell Biochem. 2004 Feb 15;91(3):459-77; Reliene R, Schiestl RH. Antioxidants suppress lymphoma and increase longevity in ATM-deficient mice. J Nutr. 2007 Jan;137(l):229S-32S ). ROS alters the activity of thiol-dependent enzymes, changes the cellular redox balance and covalently modifies proteins and modifies and mutagenizes DNA (Sikka SC, Curr Med Chem. 2001 Jun;8(7):851-62. Kamat AM, Lamm DL. W V Med J. 2000; 96: 449-54.). It has also been shown that increased lipid peroxidation and production of high levels of unregulated ROS in men with high fat diets is one of the major reasons for the higher incidence of prostate cancer in industrialized nations, as compared to that in developing countries (Dargel, R., Exp Toxic Pathol 1992, 44:169-181). In recent years, direct experimental evidence has linked increased ROS levels with the corresponding increase in mutations and tumor development in various tissues, including in the pancreas and the prostate organs (Oberley et.al., The Prostate, 2000: 44: 144-155). For example, Oberley and his colleagues monitored oxidative stress induced enzymes and oxidative damage to DNA bases of malignant and normal human prostate tissues. Malignant prostate tumor tissues showed significantly higher oxidative stress and ROS-induced DNA
modifications as compared to normal prostate tissues. Ho and her coworkers (Tarn et al., Prostate. 2006 Jan l;66(l):57-69) demonstrated the presence of high oxidative stress induced DNA modifications in the pre-neoplastic lesions occurring in the well studied TRAMP (Transgenic Adenocarcinoma of Mouse Prostate) and Noble rat (Tarn et al., Sex Hormones induce direct epithelial and inflammation-mediated oxidative/nitrosative stress that favors prostatic carcinogenesis in the Noble rat. Am. J. Pathol. 2007 Oct. 117(4);1334-41, Epub. 2007 Aug. 23.) prostate cancer mouse model of human prostate cancer.
Hence, unregulated mitochondrial ROS production, the resulting oxidative cellular damage-induced-carcffiogenesis represent unsolved problems in the art, and present a compelling target for pharmacological drug interventions with pharmaceutical anti- superoxide small molecule drug formulations.
To prevent the cellular damage caused by oxidative stress a number of prior art antioxidant therapies have been developed for treating various diseases resulting from oxidative stress. However, most of those inventions are not targeted to other organelles within cells or to the mitochondria and are therefore less than optimally effective.
In recent years, there has been interest in mitochondria-targeting technologies (see Murphy MP. "Selective targeting of bioactive compounds to mitochondria." Trends Biotechnol 1997 Aug;15(8):326-30). In these approaches, "warhead" groups are covalently coupled via linker groups to a bulky and/or lipophilic cationic moiety such as a quaternary ammonium or phosphonium cationic moiety. These compounds are initially absorbed and accumulate in the cytoplasmic region of cells in response to the negative plasma membrane potential of 30-60 mV (3). Additionally, within a few minutes after drug treatment, the lipophilic cations with a positive 30-6OmV potential permeate through the mitochondrion's lipid layers and selectively accumulate within mitochondria due to the larger mitochondrial membrane potential of 150-170 mV; (negative inside).
Mitochondria-targeted compounds in this class of agents are shown below and include a mitochondria-directed ubiquinone (MitoQ) reported by Murphy and coworkers (U.S. Patent Nos. 6,331,532 and 7,232,809, and EP Patent 1 047 701 Bl, all of which are herein incorporated by reference in their entirety).
"MitoQIO"
MitoQ has shown promise in the treatment of only some, but not all, oxidative stress induced diseases. MitoQ is currently undergoing Phase II clinical trials for the treatment of Parkinson's disease, but it has relatively minor activity against other oxidative stress-induced neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease). This class of compounds is also disclosed in U.S. Published Application No. U.S. 2008/0032940, herein incorporated by reference in its entirety, in the context of methods for treating cancer.
Other classes of mitochondria-targeted compounds include mitochondria-targeted nitroxides, which have been used in method for treating neurodegenerative disorders (see U.S. Published Application No. 2007/0066572, herein incorporated by reference in its entirety) and mitochondria-targeted antioxidants, which have been used in methods for treating cancer (see U.S. Application No. 11/834,799, entitled "Methods for Reducing Anthracycline-Induced Toxicity," filed August 7, 2007, herein incorporated by reference in its entirety).
Accordingly, there remains a need for mitochondrially targeted anti-inflammatory, antiproliferative anti-cancer agents with improved properties and/or toxicity profiles and it is towards the provision of such anti-oxidants, which maybe targeted to mitochondria that the various inventions disclosed and described below are directed.
SUMMARY
One aspect of the disclosure relates to methods for treating or inhibiting the occurrence, recurrence, progression or metastasis, of a cancer or a neoplastic or hyper- proliferative precursor thereof, consisting of administering to a mammal diagnosed as having a cancer or precursor neoplasia or hyper-proliferative disorder thereof, in an amount effective to treat the cancer or inhibit the occurrence recurrence, progression, or metastasis of the
cancer or precursor hyperplasia or neoplasia thereof, a pharmaceutically acceptable salt comprising one or more cations having the formula:
R1"'
I ®
A L E R,"
R ,1 wherein a) A is an antioxidant moiety comprising one or more nitroxide or hydroxyl amine moieties, or a pro-drug thereof, having from three to 16 carbon atoms, b) L is an organic linking moiety comprising 4 to 30 carbon atoms, c) E is a nitrogen or phosphorus atom, d) R1 ' , Ri " , and Rj " ' are each independently selected organic moieties comprising between 1 and 12 carbon atoms, wherein E, Ri', Ri", and Ri'" together form a quaternary ammonium or phosphonium cation; and wherein the salt further comprises one or more Xm" pharmaceutically acceptable anions, where m is an integer from 1 to 4, in sufficient quantities to form the pharmaceutically acceptable salt.
A related aspect of the disclosure relates to a method for treating, regulating or inhibiting the prostate's inflammation, hyperplasia or enlargement and the occurrence, recurrence, progression or metastasis of prostate cancer, consisting of administering to a mammal diagnosed as having prostate disease or cancer or precursor neoplasia thereof, in an amount effective to treat the cancer or modulate the inflammation, hyperplasia, or enlargement of the prostate or the occurrence, recurrence, progression, or metastasis of prostate cancer or precursor neoplasia thereof, with one or more pharmaceutically acceptable salts having one or more cations having the formula
wherein a) E is a nitrogen or phosphorus atom,
b) Rf', Ri", and Rj'" are each independently selected organic moieties comprising between 1 and 12 carbon atoms, c) n is an integer between 8 and 12, and d) R s ' , Ri " , and R j " ' are each independently selected organic moieties comprising between 1 and 12 carbon atoms, wherein E, R1', Ri", and Ri'" together form a quaternary ammonium or phosphonium cation; wherein the salt further comprises one or more pharmaceutically acceptable anions Xm", wherein m is an integer from 1 to 4, in sufficient amount to form the pharmaceutically acceptable salt.
In other related aspects, the inventions described and disclosed herein relate to salts comprising one or more cations having the formula:
or or
or or
wherein a) E is a nitrogen or phosphorus atom, b) R i ' , R i " , and R1 '" are each independently selected organic moieties comprising between 1 and 12 carbon atoms, c) n is an integer between 5 and 12, and wherein E, Ri', R1", and R1'" together form a quaternary ammonium or
phosphonium cation; and wherein the salt forther comprises is one or more pharmaceutically acceptable anions Xm~, wherein m is an integer from 1 to 4, in sufficient amount to form the pharmaceutically acceptable salt.
Another aspect of the disclosure relates to salts comprising one or more cations having the formula:
or or
or or
wherein a) E is a nitrogen or phosphorus atom, b) R] ', Ri ", and Ri '" are each independently selected organic moieties comprising between 1 and 12 carbon atoms, c) n is an integer between 5 and 12, and wherein E, Ri', Rj", and Rj '" together form a quaternary ammonium or phosphonium cation; and wherein the salt further comprises one or more anions Xm' in a sufficient amount to form the pharmaceutically acceptable salt.
It is understood that the examples and embodiments described above are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of
this application and scope of the appended claims.
Additional aspects of the inventions and advantages thereof will be set forth in part in the description which follows and in part will be obvious from the description, or may be learned by practice of the aspects described below. The advantages described below will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive.
BRIEF DESCRIPTION OF THE DRAWINGS
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several aspects described below. Like numbers represent the same elements throughout the figures.
Figure 1 shows the inhibitory effect of varying concentrations of MitoT on the proliferation and growth of human prostate tumor LNCaP and PC-3 cells, as determined by Hoechst dye-DNA fluorescence assays. Figure 2 shows a microscopic picture of DCF fluorescence (green) and Hoechst dye-
DNA fluorescence (blue) in human prostate tumor LNCaP cells, which have been placed under high oxidative stress due to treatment of the cells with a 1 nM solution of the synthetic androgen analog, Rl 881.
Figure 3 shows the inhibitory effect of treatment with varying concentrations of MitoT on the oxidative stress levels in LNCaP human prostate tumor cells, as determined by the ratio of DCF fiuorescence/Hoechst dye-DNA fluorescence.
Figure. 4 shows that MitoT treatment at sufficient concentrations reduces the ROS level and causes inhibition of cell growth and proliferation in LNCaP human prostate cancer cells (A) Plot of % control of MTT absorbance at increasing MitoT concentration shows MitoT absorbs mitochondrial electrons. (B) Plot of the ratio of % of control cell MTT absorbance/DNA fluorescence shows that the decrease in MTT oxidation is related to cell growth arrest.
Figure 5 shows that synthetic androgen (Rl 881) treatment-induced oxidative stress in LNCaP human prostate cancer cells, as determined by the ratio of DCF fluorescence/DNA fluorescence, is strongly inhibited by pre-treatment of the ceils with 1 μM MitoT.
Figure 6 shows the pharmacokinetics of MitoT absorption in serum and in kidney
tissues of white mice given one intraperitoneal ( i.p.) injection of MitoT (5 mg/kg) showing serum clearance and tissue accumulation of the drug with the passage of time.
Figure 7 shows pictorial microscopic evidence of Hydroethidine dye fluorescence due to ROS oxidation in kidney tissue of (A) untreated mice and (B) mice treated with 5 mg/kg MitoT for 3 hours.
Figure 8 shows the inhibitory effect of varying concentrations of MitoT- 10 on the growth and proliferation of LNCaP and PC-3 human prostate cancer cells, as determined by Hoechst dye-DNA fluorescence assays
DETAILED DESCRIPTION Before the disclosure is described in detail, it is understood that scope of this disclosure is not limited to the particular methodology, protocols, cell lines, and reagents described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the disclosure, which will be limited only by the appended claims. It must be noted that as used herein and in the appended claims, the singular forms
"a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art, and so forth. As well, the terms "a" (or "an"), "one or more "and "at least one" can be used interchangeably herein. It is also to be noted that the terms "comprising", "including", and "having" can be used interchangeably.
Often, ranges are expressed herein as from "about" one particular value, and/or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another embodiment. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.
"Optional" or "optionally" means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. For example, the phrase "optionally substituted lower alkyl" means that the lower alkyl group can or can not be substituted and
that the description includes both unsubstituted lower alkyl and lower alkyl where there is substitution.
A cell can be in vitro. Alternatively, a cell can be in vivo and can be found in a subject. A "cell" can be a cell from any organism including, but not limited to, a bacterium or a mammalian cell or a tumor cell.
As used throughout, by a "subject" is meant an individual. Thus, the "subject" can include domesticated animals, such as cats, dogs, etc., livestock (e.g., cattle, horses, pigs, sheep, goats, rabbits, etc.), laboratory animals (e.g., mouse, rabbit, rat, guinea pig, ferret, mink, etc.) and birds. In one aspect, the subject is a higher mammal such as a primate or a human.
In one aspect, the compounds described herein can be administered to a subject comprising a human or an animal including, but not limited to, a murine, canine, feline, equine, bovine, porcine, caprine or ovine species and the like, that is in need of alleviation or amelioration from a recognized medical condition. References in the specification and concluding claims to parts by weight, of a particular element or component in a composition or article, denotes the weight relationship between the element or component and any other elements or components in the composition or article for which a part by weight is expressed. Thus, in a compound containing 2 parts by weight of component X and 5 parts by weight component Y, X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.
A weight percent of a component, unless specifically stated to the contrary, is based on the total weight of the formulation or composition in which the component is included.
The term "moiety" defines a carbon containing residue, i.e. a moiety comprising at least one carbon atom, and includes but is not limited to the carbon-containing groups defined hereinabove. Organic moieties can contain various heteroatoms, or be bonded to another molecule through a heteroatom, including oxygen, nitrogen, sulfur, phosphorus, or the like. Examples of organic moieties include but are not limited alkyl or substituted alkyl s, alkoxy or substituted alkoxy, mono or di-substituted amino, amide groups, etc. Organic moieties can preferably comprise 1 to 21 carbon atoms, 1 to 18 carbon atoms, 1 to 15, carbon atoms, 1 to 12 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms.
Unless defined otherwise, all technical and scientific terms used herein have the same
meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the chemicals, cell lines, vectors, animals, instruments, statistical analysis and methodologies which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention. The term "alkyl" denotes a moiety containing a saturated, straight or branched hydrocarbon residue having from 1 to 18 carbons, or preferably 4 to 14 carbons, 5 to 13 carbons, or 6 to 10 carbons. An alkyl is structurally similar to a non-cyclic alkane compound modified by the removal of one hydrogen from the non-cyclic alkane and the substitution, therefore, with a non-hydrogen group or moiety. Alkyl moieties can be branched or unbranched. Lower alkyl moieties have 1 to 4 carbon atoms. Examples of alkyl moieties include methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, t-butyl, amyl, t-amyl, n-pentyl and the like.
The term "substituted alkyl" denotes an alkyl moiety analogous to the above definition that is substituted with one or more organic or inorganic substituent moieties. In some embodiments, 1 or 2 organic or inorganic substituent moieties are employed. In some embodiments, each organic substituent moiety comprises between 1 and 4, or between 5 and 8 carbon atoms. Suitable organic and inorganic substituent moieties include, but are not limited to, hydroxyl, halogens, cycloalkyl, amino, mono -substituted amino, di-substituted amino, acyloxy, nitro, cyano, carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide, alkylsulfonyl, alkylsulfinyl, thioalkyl, thiohaloalkyl, alkoxy, substituted alkoxy, haloalkyl, haloalkoxy, heteroaryl, substituted heteroaryl, aryl or substituted aryl. When more than one substituent group is present then they can be the same or different. Abbreviations used herein include: The term "alkoxy" as used herein denotes a moiety alkyl, defined above, attached directly to a oxygen to form an ether residue. Examples include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, t-butoxy, iso-butoxy and the like.
The term "substituted alkoxy" denotes a alkoxy moiety of the above definition that is substituted with one or more groups, but preferably one or two substituent groups including
hydroxyl, cycloalkyl, amino, mono -substituted amino, di-substituted amino, acyloxy, nitro, cyano, carboxy, carboalkoxy, alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide, alkylsulfonyl, alkylsulfinyl, thioalkyl, thiohaloalkyl, alkoxy, substituted alkoxy or haloalkoxy. When more than one group is present then they can be the same or different.
The term "mono-substituted amino" denotes an amino (-NH2) group substituted with one group selected from alkyl, substituted alkyl or arylalkyl wherein the terms have the same definitions found throughout.
The term "di-substituted amino" denotes an amino substituted with two moieties that can be same or different selected from aryl, substituted aryl, alkyl, substituted alkyl or arylalkyl wherein the terms have the same definitions found throughout. Some examples include dimethylamino, methylethylamino, diethylamino and the like.
The term "haloalkyl" denotes a alkyl moiety, defined above, substituted with one or more halogens, preferably fluorine, such as a trifluoromethyl, pentafluoroethyl and the like. The term "haloalkoxy" denotes a haloalkyl, as defined above, that is directly attached to an oxygen to form a halogenated ether residue, including trifluoromethoxy, pentafluoroethoxy and the like.
The term "acyl" denotes a moiety of the formula -C(O)-R that comprises a carbonyl (C=O) group, wherein the R moiety is an organic moiety having a carbon atom bonded to the carbonyl group. Acyl moieties contain 1 to 8 or 1 to 4 carbon atoms. Examples of acyl moieties include but are not limited to formyl, acetyl, propionyl, butanoyl, iso-butanoyl, pentanoyl, hexanoyl, heptanoyl, benzoyl and like moieties.
The term "acyloxy" denotes a moiety containing 1 to 8 carbons of an acyl group defined above directly attached to an oxygen such as acetyloxy, propionyloxy, butanoyloxy, iso -butanoyloxy, benzoyloxy and the like.
The term "aryl" denotes an unsaturated and conjugated aromatic ring moiety containing 6 to 18 ring carbons, or preferably 6 to 12 ring carbons. Many aryl moieties have at least one six-membered aromatic "benzene" moiety therein. Examples of such aryl moieties include phenyl and naphthyl. The term "substituted aryl" denotes an aryl ring moiety as defined above that is substituted with or fused to one or more organic or inorganic substituent moieties, which include but are not limited to a halogen, alkyl, substituted alkyl, haloalky, hydroxyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, amino, mono- substituted amino, di-substituted amino, acyloxy, nitro, cyano, carboxy, carboalkoxy,
alkylcarboxamide, substituted alkylcarboxamide, dialkylcarboxamide, substituted dialkylcarboxamide, alkylsulfonyl, alkylsulfinyl, thioalkyl, thiohaloalkyl, alkoxy, substituted alkoxy or haloalkoxy, aryl, substituted aryl, heteroaryl, heterocyclic ring, substituted heterocyclic ring moiety, wherein the terms are defined herein. Substituted aryl moieties can have one, two, three, four, five, or more substituent moieties. The substituent moieties can be not be of unlimited size or molecular weight, and each organic moiety can comprise 15 or fewer, 10 or fewer, or 4 or fewer carbon atoms unless otherwise expressly contemplated by the claims
The term "heteroaryl" denotes an aryl ring moiety as defined above, wherein at least one of the carbons of the aromatic ring has been replaced with a heteroatom, which include but are not limited to nitrogen, oxygen, and sulfur atoms. Heteroaryl moieties include 6 membered aromatic ring moieties, and can also comprise 5 or 7 membered aromatic rings, or bicyclic or polycycMc heteroaromatic rings as well. Examples of heteroaryl moieties include pyridyl, bipyridyl, furanyl, and thiofuranyl residues. It is to be understood that the heteroaryl moieties can optionally be substituted with one or more organic or inorganic substituent moieties bound to the carbon atoms of the heteroaromatic rings, as described hereinabove for substituted aryl moieties. Substituted heteroaryl moieties can have one, two, three, four, five, or more substituent organic or inorganic moieties, in a manner analogous to the substituted aryl moieties defined herein. The substituent moieties cannot be of unlimited size or molecular weight, and each organic substituent moiety can comprise 15 or fewer, 10 or fewer, or four or fewer carbon atoms unless otherwise expressly contemplated by the claims. The term "halo," "halide," or "halogen" refers to a fluoro, chloro, bromo or iodo atom or ion.
The term "heterocycle" or "heterocyclic", as used in the specification and concluding claims, refers to a moiety having a closed ring structure comprising 3 to 10 ring atoms, in which at least one of the atoms in the ring is an element other than carbon, such as, for example, nitrogen, sulfur, oxygen, silicon, phosphorus, or the like. Heterocyclic compounds having rings with 5, 6, or 7 members are common, and the ring can be saturated, or partially or completely unsaturated. The heterocyclic compound can be monocyclic, bicyclic, or polycyclic. Examples of heterocyclic compounds include but are not limited to pyridine, piperidine, thiophene, furan, tetrahydrofuran, and the like. The term "substituted heterocyclic" refers to a heterocyclic moiety as defined above having one or more organic or inorganic substituent moieties bonded to one of the ring atoms.
The term "carboxy", as used in the specification and concluding claims, refers to the -
C(O)OH moiety that is characteristic of carboxylic acids. The hydrogen of the carboxy moieties is often acidic and (depending on the pH) often partially or completely dissociates, to form an acid H+ ion and a carboxylate anion (-CO2 "), wherein the carboxylate anion is also sometimes referred to as a "carboxy" moiety. It is understood that when a chiral atom is present in a compound disclosed herein, both separated enantiomers, racemic mixtures and mixtures of enantiomeric excess are within the scope of the invention. Separation of such mixtires may be done using techniques known in the art. As defined herein, a racemic mixture is an equal ratio of each of the enantiomers, whereas an enantiomeric excess is when the percent of one enantiomer is greater than the other enantiomer, all percentages are within the scope of the invention. Furthermore, when more than one chiral atom is present in a compound, then the enantiomers, racemic mixtures, mixtures of enantiomeric excess and diastereomic mixtures are within the scope of the invention.
II. THE INVENTIONS Compounds Employed in the Inventions
The compounds described below are salts, and can be used for the treatment of various diseases as disclosed elsewhere herein. As will be appreciated by those of ordinary skill in the art, the salts comprise a mixture of cations and anions whose total number of positive and negative charges are electrically balanced. More particularly, however, the salts disclosed herein have one or more cations having the Formula (I) illustrated below ©
(I) wherein a) A is an antioxidant moiety comprising one or more nitroxide or hydroxylamine moieties, or a prodrug thereof, b) L is an organic linking moiety, c) E is a nitrogen or phosphorus atom, d) Rj ', Ri ", and R5 '" are each independently selected from organic moieties comprising between 1 and 12 carbon atoms, wherein E, Ri', Ri", and R1'" together form a quaternary ammonium or
phosphonium cation ; and wherein the salt further comprises is one or more pharmaceutically acceptable anions Xm", wherein m is an integer from 1 to 4, in sufficient amount to form the pharmaceutically acceptable salt. The various genera, subgenera, and species of the compounds of Formula (I) share at least the features disclosed above, and have related functions and utilities, but can differ in specific structural features, as described below.
The Antioxidant "A" Moieties
The compounds of the invention all comprise at least one antioxidant moiety "A" which comprises at least one or more nitroxide radial or hydroxyl amine moieties bonded therein or thereto.
Nitroxides and relevant hydroxylamines have the chemical structures shown below:
N — O - or N — OH
•*' < nitroxides hydroxylamines It is well known, as explained above, that superoxide anion is formed in relatively large concentrations in the mitochondria of cells, and that excess concentrations of superoxide are deleterious to the mitochondria and other parts of the cell. It is well known in the art that nitroxides and/or hydroxylamines can function to catalyze the dismutation of superoxide anion in the fashion illustrated below.
Xr Js
\ : \
N O - + O2 + H+ — >- N — OH + O2
/ / ^ ^ nitroxide superoxide hydroxylamine
Xr Xr N OH + O2 * + H *~ N O - + H2O2
hydroxylamine superoxide nitroxide
2O2 " + 2H+ *~ O2 + H2O2
Accordingly, the "A" moieties of the salts described herein, which comprise one or more nitroxide orhydroxyl amine moieties, can catalyze the dismutation of superoxide radical anions in the cell, to form hydrogen peroxide which can be dealt with by enzymes in the cell, and therefore serve to function as "anti-oxidants." The nitroxide or hydroxylamine moieties are part of a larger A moiety, which in many embodiments can comprise between 4 and 30 carbon atoms, or, 6 to 24 carbon atoms, or 7 to 18 carbon atoms, or from 8 to 12 carbon atoms.
In some embodiments, the A moieties have 5 or 6-member rings containing a nitroxide free radical therein having the formulas:
5 and 6-member rings containing a hydroxyl amine moiety having the formula:
wherein the R moieties are organic substitutent moieties. In some embodiments, the R moieties can be C, -C4 alkyls, aryls, alkoxides, and the like. In some embodiments, the R moieties can be C1-C4 linear or branched alkyl, for example, methyl (C1), ethyl (C2), n-propyl
(C3), ϊsø-propyl (C3), n-butyl (C4), sec-butyl (C4), iso-butyl (C4), and tert-butyl (C4).
In many embodiments, the R2 moieties are all methyl groups as shown below, which are [2,2,5,5-tetramethylpyrrolidinyloxy] free radical having the formula:
Similar A moieties having corresponding hydroxylamine moieties are 2,2,5,5- tetramethylpyrrolidin-1-ols having the formula:
Such compounds comprising the five membered nitroxide or hydroxyl amine moieties
incorporated into such five-membered heterocycles are often referred to in the art as "Proxyl" derivatives.
In other embodiments, the "A" moieties are [2,2,6,6-tetramethylpiperidinyloxy] free radical moieties the formula:
or 2,2,6,6-tetramethylpiperidin-l-ol moieties having the formula:
Such compounds comprising a nitroxide or hydroxyl amine moieties incorporated into such six-membered heterocycles are often referred to in the art as "Tempol" derivatives.
In the Proxyl or Tempol analogs shown above, Lg can be any of a variety of moieties that form a bond to the "L" linking group. In many embodiments, Lg can be one of the following moieties: -O, -CH2-; -CH2-O-, -CH2-NH-, -NR3-, -NR3C(O)-; -C(O)N R3-, - C(O)O-, -C(O)-, -OC(O)-, -NHC(O)NH-, or -NH(=NH)NH-, wherein R3 is hydrogen or a linear or branched CrC4 alkyl, for example, methyl (C1), ethyl (C2), n-propyl (C3), iso- propyl (C3), n-butyl (C4), sec-butyl (C4), iso-buty\ (C4), and tert-butyi (C4).
In some embodiments, the Lg moieties taken together with nitroxide free radical moieties can provide "Tempol" analog moieties having the formula:
or any of the similar hydroxyl amine moieties having the formulas;
In some embodiments, the Lg moieties taken together with nitroxide free radical moieties can provide "Proxyl" analog moieties having the formula:
or any of the similar hydroxyl amine moieties having the formulas:
L moieties serve to connect the quaternary ammonium and/or phosphonium salt moieties with the A moieties. L moieties can comprise a polyalkylene chain having 5 to 30 carbon chain atoms, wherein any one or more of the hydrogens bonded to said carbon chain atoms can be optionally substituted with one or two independently selected hydroxyl, halogen, amino, methylamino, dimethylamino, or C]-C4 organic moieties selected from alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties.
The Ammonium or Phosphonium Cationic Moieties
The compounds useful for the methods of the disclosure comprise one or more cationic moieties. The cationic moieties carry a positive charge, which, while not being bound by theory, is believed to cause the desirable selective accumulation of the resultant compounds in the mitochondria, because of the large mitochondrial membrane potential of 150- 170 mV, and the resulting electrostatic attractions. Again, while not being bound by theory, it has been found that the selective accumulation of the cationic salts disclosed herein is also improved if the cationic moieties comprise relatively large and/or lipophilic organic substitutent moieties, so that the resulting cationic group is relatively lipophilic when considered as a whole. One of ordinary skill in the art will recognize that many relatively Hpophillic cationic groups can be synthesized, especially from compounds comprising nitrogen or phosphorus atoms, and it is evident that many such cationic moieties could be linked in various ways to the antioxidant A moieties, and provide a cation that might be useful in the practice of the methods described herein. More particularly however, in many embodiments of the salts and/or cationic compounds of Formula (I) have quaternary ammonium or phosphonium moieties, having the formula:
wherein:
E is a nitrogen or phosphorus atom; and
Ri', Ri", and Rj'" are each independently organic moieties comprising from 1 to 32 carbon atoms.
In many embodiments, the compounds of Formula (I) can have Rb, R1", and R1"' are each independently selected from alkyl, aryl, heteroaryl, or aralkyl moieties, which may be unsubstituted, or optionally substituted with one or two independently selected substituent moieties, such as those described above, which include but are not limited to hydroxyl, halogen, amino, amino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties. Non-limiting examples of the optional substituents for R1', R1", and R1'" include: i) CrC4 linear branched alkyl; for example, methyl (Cj), ethyl (C2), n-propyl
(C3), fso-propyl (C3), n-butyl (C4), .sec-butyl (C4), iso-bntyl (C4), and tert-butyl
(C4); ii) Ci-C4 linear or branched alkoxy; for example, methoxy (Ci), ethoxy (C2), n- propoxy (C3), wo-propoxy (C3), n-butoxy (C4), sec-butoxy (C4), iso-bntoxy (C4), and tert-butoxy (C4) ; iii) halogen; for example, -F, -Cl, -Br, -I, and mixtures thereof; iv) amino and substituted amino; for example, -NH2, -NH2, -NHCH3, -NHCH3, and -N(CH3)2; v) hydroxyl; -OH; vi) Ci-C4 linear or branched hydroxyalkyl; for example, -CH2OH, -CH2CH2OH,
-CH2CH2CH2OH, and -CH2CHOHCH3; vii) Ci-C4 linear or branched alkoxyalkyl; for example, -CHiOCH3, -CH2CH2OCH3, -CH2CH2CH2OCH3, and -CH2CH(OCH3)CH3; viii) carboxy or carboxylate, for example, -CO2H or the anionic equivalent carboxylate moieties -CO2 " ; and xi) carboxyalkyl, for example, -CH2CO2H, -CH2CH2CO2H, -CH2CO2CH3, -CH2CH2CO2CH3, and -CH2CH2CH2CO2CH3.
In related embodiments, Ri', Ri", and R1'" can be each independently selected from alkyl, aryl, or benzyl moieties optionally substituted with one or two independently selected hydroxyl, halogen, amino, diamino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties.
In other related embodiments, R1', R1", and R1'" can be independently selected from
C4-C10 alkyl or phenyl moieties, which can optionally be substituted with one or two independently selected substituent moieites, which can include but are not limited to hydroxyl, halogen, amino, diamino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, cyano,carboxy, or carboxyalkyl moieties. In additional embodiments, R1', R!", and R1'" can be independently selected from C4-C10 alkyl or phenyl moieties. In some additional embodiments R1', R1", and R1'" are independently selected from C4-C10 alkyl. In yet other related embodiments R1', R1", and R1'" are each n-C4H9 moieties.
In some embodiments of the compounds of Formula (I) having phosphonium cations, R1', R1", and R1'" are each phenyl moieties, to produce triphenyl phosphonium cations having the formula:
In alternative but related embodiments, R1', R1", and R1'" are each benzyl moieties, to produce tribenzyl phosphonium cations having the formula:
Other embodiments of the cations of Formula (I) relates to quaternary ammonium cations, i.e. wherein E is a nitrogen atom. In some such embodiments, R1', R1", and R1'" are each independently selected from alkyl, aryl, heteroaryl, or aralkyl moieties, which can be optionally substituted with one or two independently selected substituent moieties, which include but are not limited to hydroxyl, halogen, amino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, cyano, carboxy, or carboxyalkyl moieties. Non-limiting examples of the R1', R!", and R1'" substituents include: i) C]-C4 linear branched alkyl; for example, methyl (CO, ethyl (C2), n-propyl
(C3), wo-ρropyl (C3), n-butyl (C4), sec-butyl (C4), iso-bntyl (C4), and tert-butyl (C4);
ϋ) C1-C4 linear or branched alkoxy; for example, methoxy (Cj), ethoxy (C2), n- propoxy (C3), /so-propoxy (C3), n-butoxy (C4), sec-butoxy (C4), irø-butoxy
iii) halogen; for example, -F, -Cl, -Br, -I, and mixtures thereof; iv) amino and substituted amino; for example, -NH2, -NH2, -NHCH3, -NHCH3, and -N(CH3)2; v) hydroxyl; -OH; vi) Ci-C4 linear or branched hydroxyalkyl; for example, -CH2OH, -CH2CH2OH,
-CH2CH2CH2OH, and -CH2CHOHCH3; vii) Q-C4 linear or branched alkoxyalkyl; for example, -CH2OCH3,
-CH2CH2OCH3, -CH2CH2CH2OCH3, and -CH2CH(OCH3)CH3; viii) carboxy; or carboxylate, for example, -CO2H or the anionic equivalent carboxylate moieties -CO2 " ; and xi) carboxyalkyl, for example, -CH2CO2H, -CH2CH2CO2H, -CH2CO2CH3, -CH2CH2CO2CH3, and -CH2CH2CH2CO2CH3.
In additional embodiments of the cations of Formula (I), wherein E is nitrogen, R]', Ri", and Ri'" are each independently selected from alkyl aryl, or benzyl moieties, which can be optionally substituted with one or two independently chosen substitutent moieties, such as those described above, which include but are not limited hydroxyl, halogen, amino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties.
In another embodiment R1', R1", and R1"' are independently selected from C4-CjO alkyl or phenyl moieties optionally substituted with one or two independently selected hydroxyl, halogen, amino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties. In one further aspect of this embodiment R1', R1", and R1'" are independently selected from C4-C JO alkyl or phenyl moieties; and in one further embodiment R1', R1", and R1'" are independently selected from C4-CiO alkyl.
In yet another embodiment of cations wherein E is nitrogen, RI ?, R1", and R1'" are each n-C4Hg moieties.
The "L" Linker Moiety The cations of Formula (I) comprise a linker moiety "L", which connects the "A" moiety and the cationic moiety. The exact structure and size of the L moieties can vary considerably, and many variations of the L moieties are within the scope of the inventions
disclosed herein. In some the L moieties are often organic moieties, and can comprise a wide variety of structures. In many embodiments it is desirable that the L moiety be of sufficient size and character that it provides some space and/or flexibility in the connection between the A and cation groups, but does not become of such high molecular weight so as to impair the water solubility or trans-membrane absorbability of the resulting cations.
Accordingly, in some embodiments, the L moiety, when considered as a whole, comprises from about 4 and 30 carbon atoms, or from about 4 and 20 carbon atoms. In some embodiments, the L moiety comprises from 6 to 18 carbon atoms, or from 8 to 12 carbon atoms. In some embodiments, the L moieties can comprise only methylene or polymethylene moieties, i.e. -(CHa)n- moieties. Some embodiments provide L having from 5 to 24 carbon chain atoms, for example, -(CHa)n-, wherein the index n is from 5 to 24. Another embodiment relates to L having from 5 to 20 carbon chain atoms, for example, -(CH2)H-, wherein the index n is from 5 to 20. A further embodiment relates to L having from 6 to 16 carbon chain atoms, for example, -(CH2)J1-, wherein the index n is from 6 to 16. A yet further embodiment relates to L having from 7 to 16 carbon chain atoms, for example, - (CH2)n-, wherein the index n is from 7 to 16. A still yet further embodiment relates to L having from 8 to 12 carbon chain atoms, for example, -(CHa)n-, wherein the index n is from 8 to 12. One particular example is an L unit comprising 10 methylene moieties having the formula: "-CH2CH2CH2CH2CH2CH2CH2CH2CH2CH2- wherein n = 10.
Nevertheless, the L moieties can further comprise in the carbon chain from 1 to 10 additional atoms or groups independently selected from -O-, -S-, -S(O)-, -S(O)2-NH-, - NCH3-, -C(O)-, or -CO2- moieties. For example, in some embodiments, L can be a polyalkylene glycol moiety, or a polyethylene glycol moiety, having the structure
5-/cH2 CH2 -θVcH2 CH2 -O — < n wherein n is an integer from 0 to 3.
It is to be understood that in some embodiments, the L moiety can comprise therein or thereon an additional ionic substituent moiety, so the electrical charge of the cation of Formula (1) could be increased or decreased. In particular, the L moiety can comprise an additional one or two quartemary ammonium or phosphonium moiety therein, so that the overall electrical charge of the cation of Formula I could be 2+ or 3+, so as to be a dication,
or trication. Such dicationic or tricationic compounds can provide even higher water solubility and/or selectivity of absorption into mitochondria than compounds of Formula (I) that are only monocationic.
The Xm' Anions The salt compounds comprising the cations of Formula(I) also comprise an anion Xm, wherein m is an integer from 1 to 4, corresponding to monoanions, di-anions, tri-anions, and tetra-anions. The first iteration of X' relates to inorganic anion moieties. Mono -anionic inorganic anions include any halide anion, such as fluoride, chloride, bromide, or iodide; nitrate, hydrogen sulfate; dihydrogen phosphate, and the like. Dianionic inorganic cations can include carbonate, sulfate or hydrogenphosphate, and tri-anionic inorganic anions include phosphates.
In other embodiments of the Xm~ anions, the anions are organic anions. Non-limiting examples of organic anion moieties that can be employed to form the salts from the cations of Formula (I) include organosulphates such as methylsulphonate (mesylate), trifluoromethylsulfonate (inflate), benzenesulphonate, toluenesulphonate (tosylate), or purely organic anions, often formed by the neutralization of organic acids, such as fumarate, maleate, maltolate, succinate, acetate, benzoate, oxalate, citrate, or tartrate anions.
Those of ordinary skill in the art will recognize that both the cations of Formula (I) and the corresponding Xm~ anions must be combined in appropriate ratios so as to produce isolated and electrically neutral salt compounds that can be isolated and used in the methods and compositions disclosed herein. Accordingly, one way of expressing the condition of electrical neutrality when applied to the salt compounds as a whole is to recognize that such salt compounds can have the formula:
N[cation]p+M[anion]m' wherein the indices M, N, m and p are each independently from 1 to 4, provided that the product (M x m) = (p x N) thereby forming a neutral salt.
Making the Compounds of the Inventions
Various synthetic methods and/or strategies can be employed in the synthesis or production of salts having cations of Formula (I) and Xm" anions, as described above and in the examples below. Several such synthetic methods and/or strategies will be disclosed herein below.
Compounds wherein Lt is Oxygen
The [4-(tri-organophosphonium)acyloxy-2 ,2,6 ,6-tetraalkylpip eridinylo xy, free radical] salts of the present invention have the formula:
wherein R1', Rj", Ri'", R2, L, and X are defined elsewhere. These compounds can be synthesized by the following generic procedure outlined in Scheme I.
Scheme I Step (a):
A
Step (b):
B
Step (c):
The 4-substituted -2,2,6,6-tetraalkylpiperidinyloxy moieties used as starting materials for step (a) of Scheme 1 are well known in the art as "Tempol" derivatives and many such compounds are known in the art and/or readily commercially available, especially compounds wherein all R2 groups are methyls.
Step (a) encompasses removal of an H+ cation from the starting material with a strong
base, with generation of the corresponding 4-alkoxy anion. The proton can be removed by any strong organic or inorganic base which is convenient and which does not affect the R substituents. Non-limiting examples of organic bases include alkyl or aryl lithium reagents, such as phenyl lithium, methyl lithium, n-butyl lithium, tert-butyl lithium, sodium amide, lithium amide, lithium diisopropylamide, lithium dimethylamide, lithium diethylamide, and the like. The formation of the 4-alkoxy anion can be conducted in the cold, i.e. at room temperature or from O0C to -780C.
Non-limiting examples of inorganic bases include NaOH, KOH, LiOH, Ca(OH)2, Na2CO3, K2CO3, and the like. One embodiment which is described herein below utilizes NaH as the base. Other hydride bases, inter alia, KH can be utilized especially when low temperature conditions and solvent compatibility cause more reactive bases to be used. In addition, strong inorganic bases can be used to form organic bases from polar aprotic solvents, inter alia, dimethyl sulfoxide, ΛζN-dimethylacetamide, and hexamethylphosphoric triamide, for example, a dimsyl anion from dimethyl sulfoxide. Any non-reactive or aprotic solvent or mixtures of solvents can be used for Step (a).
Non-limiting examples of solvents include alkane solvents, inter alia, pentane, iso-pentane, hexane, heptane, octane, isooctane, and the like; aromatic hydrocarbon solvents, inter alia, benzene, toluene, and xylene (all isomers); ethers, inter alia, diethyl ether, tetrahydro-furan, and dioxane; and various fluorinated hydrocarbons. In addition, polar aprotic solvents can be used, inter alia, dimethyl sulfoxide, dimethylformamide, AyV-dimethylacetamide, and hexamethylphosphoric triamide.
In addition, combinations of solvents can be used. For example, typically once the anion is generated, the formulator can proceed to Step (b) without necessarily having to isolate the alkoxide, therefore, a second co-solvent may be used which enhances the solubility of the reagents used in Step (b) without affecting the formation of the anion.
Step (b) encompasses attaching a linker group L to the alkoxide generated in Step (a). The 4-alkoxide is reacted with a linker molecule L having two reactive leaving groups; Z and X. The leaving groups may be the same or different.
L is a linking group comprising from 4 to 30 carbon atoms as described herein. Z and X can be any suitable leaving group which is sufficiently reactive to allow attachment of the tether without loss of the free radical moiety. Non-limiting examples of suitable leaving groups include halogens: iodine, bromine, and chlorine; sulphonyl leaving groups, inter alia, methylsulphonyl (mesyl), ethylsulphonyl, benzenesulphonyl, toluenesulphonyl (tosyl), and the like.
Non-limiting examples of compounds having two leaving groups that can be used to as reagents in forming the linking group between the free radical portion of the molecule and the quaternary ammonium or phosphonium moiety include: i) α,ω-di-bromoalkanes, inter alia, 1 ,4-dibromobutane, 1,5-dibromopentane, 1,6- dibromohexane, 1 ,7-dibromoheptane, 1 ,8-dibromooctane, 1,9-di- bromononane, and 1,10-dibromodecane; ii) α,ω-di-chloroalkanes, inter alia, 1,4-dichlorobutane, 1 ,5-dichloropentane, 1,6- dichlorohexane, 1,7-dichloroheptane, 1,8-dichlorooctane, 1 ,9-di-chlorononane, and 1 , 10-dichlorodecane; iii) α,ω-di-iodoalkanes, inter alia, 1 ,4-diiodobutane, 1,5-diiodopentane, 1,6- dϋodohexane, 1 ,7-diiodoheptane, 1 ,8-diiodooctane, 1 ,9-di-iodononane, and 1 , 10-diiododecane; iv) α,ω-mixed leaving group alkanes, inter alia, 1 -bromo-4-chlorobutane, 1 - bromo-5-chloropentane, 1 -bromo-6-chlorohexane, 1 -bromo-10-chloro-decane, 1 -iodo-4-chlorobutane, l-iodo-5-chloropentane, l-iodo-6-chloro-hexane, 1- iodo-10-chlorodecane, 1 -iodo-4-bromobutane, l-iodo-5-bromo-pentane, 1- iodo-6-bromohexane, 1 -iodo-10-bromodecane, I -toluene-sulphonyl-4- chlorobutane, 1 -toluenesulphonyl-5-chloropentane, 1 -toluene-sulphonyl-6- chlorohexane, l-toluenesulphonyl-10-chlorodecane, l-bromo-4- toluenesulphonylbutane, l-bromo-5-toluenesulphonylρentane, l-bromo-6- toluenesulphonylhexane, 1 -bromo-10-toluenesulphonyldecane, 1 -azido-4- chlorobutane, l-azido-5-chloropentane, l-azido-6-chlorohexane, and 1-azido- 10-chlorodecane.
The formulator can take advantage of the differential reactivity of leaving groups when using α,ω-mixed leaving group alkanes for the formation of the tether. However, the formulator may wish to insert an optional Step (b)(ii) into the process for preparing the compounds of the present invention. For example, the formulator can, once intermediate B is formed, increase the reactivity of leaving group X in order to adjust for any lesser reactivity that the reagent which introduces the quaternary ammonium or phosphonium salt has. For example, in the following step l-iodo-4-chlorobutane is used to attach the first end of the tether to the free radical containing unit taking advantage of the increased reactivity of iodine as a preferred leaving group over chlorine.
wherein chlorine is replaced by iodine.
Non-limiting examples of solvents which can be used for Step (b), as well as any optional steps, inter alia, Step (b)(i), include alkane solvents, inter alia, pentane, iso-pentane, hexane, heptane, octane, isooctane, and the like; aromatic hydrocarbon solvents, inter alia, benzene, toluene, and xylene (all isomers); ethers, inter alia, diethyl ether, tetrahydro-furan, and dioxane; and various fluorinated hydrocarbons. In addition, polar aprotic solvents can be used, inter alia, dimethyl sulfoxide, dimethylformamide, ΛyV-dimethylacetamide, and hexamethylphosphoric triamide.
Step (c) encompasses forming a quaternary ammonium or phosphonium salt at the end of the linking unit opposite the end which contains the nitroxide or amine oxide moiety. For example, formation of a phosphonium salt:
B or formation of an quaternary ammonium salt:
B
However, in the case of quaternary ammonium salt containing products, Step (c) may optionally be divided into two separate steps, Step (c)(i) and Step (c)(ii), which can be
conducted either without isolation of the intermediate C or which can be conducted as two discrete steps, wherein intermediate C is isolated prior to quatemization, for example:
Step (c)(i):
Formation of a tertiary amine by displacement of the leaving group X to form intermediate C:
C which can be isolated if desired, followed by quatemization of the amine to form the final quaternary ammonium salt: Step (c)(ii):
The formulator can chose the leaving group X which comprises the alkylating agent in Step (c)(ii) to be the same as the leaving group that is displaced in Step (c)(i) or to take the opportunity to provide a different leaving group which results in the potential source of a different counter ion for the quaternary ammonium ion. However, the formulator can alternatively choose to provide the final anion by exchanging the anion present as a result of the reaction which occurs in Step (c) with another anion, and this can be done by exposing the final product to a counter ion exchange system, for example, an ion exchange resin.
In the case of forming a phosphonium salt, a tri-substituted phosphine can be directly reacted with compounds such as intermediate B to form final compounds. Examples of this reaction are found in Examples 1 and 2 herein below.
Depending upon the reactivity of the leaving group X and how nucleophilic the phosphine adduct is toward leaving group X, the reaction can be conducted over a wide range of temperatures. A first embodiment of this phosphonium forming step encompasses the reaction taking place in a refluxing solvent. Because a salt if formed, it is advantageous for the formulator to select a solvent wherein the starting materials have good solubility, but the
product which forms is either insoluble or has a reduced solubility. In this way when a stoichiometric excess of one starting reagent is used, the excess will potentially remain in solution while the desired product precipitates as an insoluble material. In addition, a co- solvent in which the product is known to be insoluble but which affords solubility to any unreacted starting material may be added to cause precipitation of the product. These same principles apply to the formation and isolation of quaternary ammonium salts formed whether in Step (c), or by way of alternative Step (c)(i) and Step (c)(ii).
Step (c) can be conducted in any non-micleophilic solvent which allows for the adequate formation of the desired product. Suitable solvents or mixtures of solvents can be used for Step (c). Non-limiting examples of solvents include alkane solvents, inter alia, pentane, iso-pentane, hexane, heptane, octane, isooctane, and the like; aromatic hydrocarbon solvents, inter alia, benzene, toluene, and xylene (all isomers); ethers, inter alia, diethyl ether, tetrahydro-furan, and dioxane; ketones, inter alia, acetone, methyl ethyl ketone, 3-pentanone; halogenated solvents, inter alia, dichloromethane, chloroform, carbon tetrachloride, 1 , 1 -dichloroethane, 1 ,2- dichloroethane, 1,1,1-trichloroethane, and various fluorinated hydrocarbons. In addition, polar aprotic solvents can be used, inter alia, dimethyl sulfoxide, dimethylformamide, N9N- dimethylacetamide, and hexamethylphosphoric triamide.
In some instances reactivity may be increased by the addition of a protic solvent, inter alia, water, methanol, ethanol, and the like, which can aid in solvation and separation of ion pairs, however, these adjustments to Step (c) are within the scope of the artisan and can be made without undue experimentation.
Scheme II outlines the preparation of a compound disclosed herein which is further described in detail in Example 1. Scheme Il
Reagents and conditions: (a) NaH, benzene; reflux, 24 hr.
Reagents and conditions: (b) 1,10-dibromodecane, benzene; reflux, 48-72 hr.
1 2
Reagents and conditions: (c) P(CnHs)3, n-propanol; reflux, 72 hr.
EXAMPLE 1
[4-(l 0-triphenylphosphonium)decyloxy-2,2,6,6-tetramethylpiperidinyloxy, free radical] bromide (2) (also known as MitoT-10, or CPC-410)
Tempo 1 (0.01 mol) was added to a three-neck flask containing 100 ml dry benzene that is maintained at nitrogen atmosphere. To the flask, sodium hydride (0.015 mol) was added and kept refluxed for 24 hrs. The flask was cooled in ice bath and added 1,10- dibromodecane (0.02 mol) in one portion. The refluxing was then resumed for another 72 hrs. The contents of the flask was cooled in ice bath and added 25ml water and transferred to a separatory funnel. The red upper benzene layer was separated , dried over anhydrous magnesium sulfate and solvent removed by rotory evaporation to get a red oil. The oil was purified by column chromatography on silica gel 60. The material was added to the column and eluted first with about 150 ml hexane that removed the excess of dibromodecane. The desired bromodecanoyl ether of Tempol was eluted with a mixture of hexane and ether
(90:10). The red eluate was collected and was found to be pure on thin layer chromatography plates developed using the same solvent mixture. The yield was 0.008 mol (80%).
The bromoether of Tempol 0.008 mol and triphenyl phosphine (0,01 mol) were taken in a flask and added 20ml of n-propanol. The contents of the flask was kept refluxed under nitrogen for 72 hrs. The flask was cooled and the solvent was removed by rotory
evaporation. The residue was dissolved in 10 ml dichloromethane and added to 100 ml ether with stirring. The precipitated product was collected by decantation of the solvent. The residual semisolid was then purified on silica gel 60 column eluting first with dichloromethane and the desired product was ehited with a mixture of dichloromethane and methanol (90:10). Homogeneous fractions combined and solvent removed to get a red-brown semisolid with a yield of 65%. Purity was ascertained by LC-MS (mass =573.4) .
Scheme III outlines the preparation of a compound disclosed herein which is further described in detail in Example 2.
Scheme III
Reagents and conditions: (a) 1,4-dibromobutane, benzene; reflux, 48-72 hr.
3 4
Reagents and conditions: (b) P(C6H5)3, dioxane; reflux, 72 hr.
EXAMPLE 2
[4-(4-triphenylphosphonium)butoxy-2,2,6,6-tetramethylpiperidinyloxy, free radical] bromide (4)
Preparation of 4-(4-bromobutoxy)~2,2,6,6-tetramethylpiperidinyloxy, free radical (3): To a 250-mL 3 -neck flask equipped with a reflux condenser and nitrogen inlet line was charged 4-hydroxy-2,2,ό,6-tetramethylpiperidinyloxy, free radical [tempol] (3.44 g, 20 mmol) and dry benzene (100 mL). Sodium hydride (0.72 g, 30 mmol) was slowly added. Once the addition was complete, the reaction was brought to reflux for 24 hours. The
resulting suspension was cooled in an ice bath and 1 ,4-dibromobutane (8.6 g, 40 mmol) was added and the solution was again brought to reflux for 24 hours. After the reaction was complete the reaction solution was cooled and water (50 mL) was added. The contents of the reaction vessel were transferred to a separatory funnel and extracted with diethyl ether (100 mL). The organic layer was decanted and dried over MgSO4 then concentrated under reduced pressure to afford the crude product containing unreacted di-bromide. The product was purified over silica [gradient eluetion: 100% hexane to 1:1 hexane/diethyl ether]. The solvent was removed in vacuo to afford 5.0 g (82% yield) of the desired product as a red oil. TLC (hexane/diethyl ether 1 :1) one spot at Rf 0.75). Preparation of [4-(4-triphenylphosphonium)dibutoxy~2,2,6,6-tetramethyl- piperidinyloxy, free radical] bromide (4): To a 3 -neck flask equipped with a reflux condenser and nitrogen inlet tube was charged 4-(10-bromobutoxy)-2,2,6,6-tetramethylpiperidinyloxy, free radical, 3, (5 g, 16.4 mmol) and dioxane (50 mL). The solution was stirred and triphenylphosphine (8 g, 30.5 mmol) was added. The mixture was then brought to reflux for 24 hours. The reaction solution was cooled and the solvent removed under reduced pressure. The residue was treated with diethyl ether (200 mL), the organic layer was decanted and the residue dissolved in CH2Cl2 (10 mL) then added to a flask containing diethyl ether (100 mL). The precipitate was collected, dissolved in CH2Cl2 and re-precipitated with diethyl ether. This procedure was repeated 3 additional times to afford 6.5 g (60% yield) of the desired product as a fluffy brown solid that is hydroscopic. The presence of the free radical was confirmed by EPR spectroscopy. LCMS MH+ 489.5.
Scheme IV outlines an example of the preparation of compounds disclosed herein wherein the linking unit is tethered to the free radical portion of the final compound by way of an ester linkage. Scheme IV
5 Reagents and conditions: (a) 4-bromobutyryl chloride, benzene; reflux.
4 6
Reagents and conditions: (b) P(C6Hs)3, dioxane; reflux.
EXAMPLE 3
4- [4-(Triphenylpho sphonium)butyryloxy-2,2 ,6 ,6-tetramethylρiperidinylo xy, free radical] bromide (6)
Preparation of 4-(4-bromobutyryloxy)-2,2,6,6-tetramethylpiperidinyloxy, free radical (5): To a 250 mL 3-neck flask equipped with a reflux condenser and nitrogen inlet line was charged 4-hydroxy-2,2,6,6-tetramethylpiperidinyloxy, free radical [tempol] (3.44 g, 20 mmol), triethylamine (2.22 g, 22 mmol) and dry benzene (100 mL). The solution was cooled in an ice bath to 0 0C. 4-Bromobutyryl chloride (3.9 g, 21 mmol) was added slowly. After the addition is complete, the solution was allowed to warm to room temperature and stir over night. The contents of the reaction vessel were transferred to a separatory funnel and extracted with water (50 mL), brine (50 mL), then dried over Na2SO4. The solvent was removed in vacuo to afford the desired product which can be used for the next step without further purification.
Preparation of 4~[4-(triphenylphosphonium)butyryloxy-2,2,6,6-tetramethyl- piperidinyloxy, free radical] bromide (6): To a 3 -neck flask equipped with a reflux condenser and nitrogen inlet tube was charged 4-(4-bromobutyryloxy)-2,2, 6,6- tetramethylpiperidinyloxy, free radical, 5, (6.42 g, 20 mmol) and dioxane (50 mL). The solution was stirred and triphenylphosphine (10.5 g, 40 mmol) was added. The mixture was then brought to reflux for 24 hours. The reaction solution was cooled and the solvent removed under reduced pressure. The residue was treated with diethyl ether (200 mL), the organic layer was decanted and the residue dissolved in CH2CI2 (10 mL) then added to a flask containing diethyl ether (100 mL). The precipitate was collected, dissolved in CH2Cl2 and re- precipitated with diethyl ether. This procedure was repeated 3 additional times to afford the desired product.
Scheme V outlines an example of the preparation of exemplary compounds disclosed herein which is further described in detail in Example 4.
Scheme V
3 7
Reagents and conditions: (a) NaI, acetone; reflux, 24 hr.
7 8
Reagents and conditions: (b) triethylamine, dioxane; reflux.
EXAMPLE 4
{4-[4-(ΛyV!!ΛLTriethylammonium)butoxy]-2,2,6,6-tetramethylpiperidinyloxy, free radical} iodide
Preparation of 4-(4-iodobutoxy)-2,2,6,6-tetramethylpiperidinyloxy, free radical (7): To a 250 mL 3 -neck flask equipped with a reflux condenser and a nitrogen inlet line is charged 4-(4-bromobutoxy)-2,2,6,6-tetramethylpiperidinyloxy, free radical, 3, (6.12 g, 20 mmol) and anhydrous acetone (50 mL). Sodium iodide (15 g, 100 mmol) that has been dried in an oven and stored in a desiccator is added in one portion. The reaction is brought to reflux for 1 hour then allowed to cool and stir overnight. Water (5 mL) is added and the volume of solvent is reduced in vacuo to approximately 20 mL. The resulting solution is extracted with CH2Cl2 (3 x 25 mL), the organic layers combined, dried over MgSO4 and concentrated in vacuo to afford the desired product which is used without further purification.
Preparation of {4-[4-(iV,7V?/Vr-triethylammonium)butoxy]-2,2,6,6-tetramethyl- piperidinyloxy, free radical} iodide (8): To a 250 mL 3-neck flask equipped with a reflux condenser is charged 4-(4-iodobutoxy)-2,2,6,6-tetramethyl-piperidinyloxy, free radical, 7,
(7.08 g, 20 iranol), triethylamine ( 20.2 g, 27.8 mL, 200 mmol), and benzene (100 niL). The reaction is warmed to 60 0C and allowed to stir overnight. The reaction is cooled to room temperature after which the reaction is poured into diethyl ether (200 mL). The resulting solution is stirred and the organic layer decanted. The solid that remains is triturated with diethyl ether, the solid collected and dried to afford the desired compound.
Compounds wherein Lg is — NH-
The [4-(triphenylphosphonium)acylamino-2,2,6,6-tetraalkylρiperidinyloxy, free radical] salts of the present invention have the formula:
wherein Rj', R1", R1'", R2, L, and X are further defined herein above. These compounds can be made by the following generic procedure outlined in Scheme VI.
Scheme VI Step (d):
D
Step (e):
D E
Step (d) encompasses attaching a tether to the free radical containing portion of the molecule. The 4-amino-2,2,ό,ό-tetraalkylpiperidinyloxy free radical is reacted with a molecule having two reactive leaving groups; Z and X. The leaving groups may be the same or different, however, Z is the group which reacts first to form the 4-acyloxy-2, 2,6,6- tetraalkyl-piperidinyloxy free radical intermediate, D, as depicted in Step (d) of Scheme VI.
Because in Step (e) described herein, a quaternary ammonium salt or phosphonium salt is formed, it is convenient for the formulator to utilize as a leaving group X, a unit that can form a stable anion and therefore act as the counter ion for the quaternary ammonium or phosphonium salt that is formed.
L is a linking group comprising from 4 to 30 carbon atoms as described elsewhere herein
Reaction procedures, conditions, solvents, reaction times, etc are similar to those employed with similar compounds wherein Lg is oxygen, and adjusting such parameters to produce useable yields of the desired products is within the level of skill of those skilled in the art of organic synthesis.
Scheme VII outlines an example of the preparation of amide compounds disclosed herein wherein the linking unit is tethered to the free radical portion of the final compound by way of an amide linkage. These compounds can be prepared by the following procedure outlined herein below.
Scheme VII
Scheme VIII
Reagents and conditions: (a) 4-bromobutyryl chloride, CH2Cl2; rt, 48-72 hr.
9 10 Reagents and conditions: (b) P(C6Hs)3, dioxane; reflux, 72 hr.
EXAMPLE 5
{4-[4-(Triphenylphosphonium)butyrylamide-2,2,6,6-tetramethylpiperidinyloxy] free radical }bromide Preparation of 4-(4-bromobutyrylamide)-2,2,6,6-tetramethylpiperidinyloxy, free radical (9): To a 250 mL 3 -neck flask equipped with a reflux condenser and nitrogen inlet line is charge 4-amino-2,2,6,6-tetramethylpiperidine-l-oxyl, free radical [4-amino -tempo] (3.44 g, 20 mmol), triethylaniine (2.22 g, 22 mmol) and dry benzene (100 mL). The solution is cooled in an ice bath to 00C. 4-Bromobutyryl chloride (3.9 g, 21 mmol) is added slowly. After the addition is complete, the solution is allowed to warm to room temperature and stir over night. The contents of the reaction vessel is transferred to a separatory funnel and extracted with water (50 mL), brine (50 mL), then dried over Na2SO4. The solvent is removed in vacuo to afford the desired product which can be used for the next step without further purification. Preparation of {4-[4-(triphenylphosphonium)butyrylamide~2,2,6,6- tetramethylpiperidinyloxy] free radical }bromide (10): To a 3 -neck flask equipped with a reflux condenser and nitrogen inlet tube is charged 4-(4-bromobutyrylamide)-2,2,6,6- tetramethylpiperidinyloxy, free radical, 9, (6.4 g, 20 mmol) and dioxane (50 mL). The solution is stirred and triphenylphosphine (10.5 g, 40 mmol) is added. The mixture is then brought to reflux for 24 hours. The reaction solution is cooled and the solvent removed under reduced pressure. The residue is treated with diethyl ether (200 mL), the organic layer is decanted and the residue dissolved in CH2CI2 (10 mL) then added to a flask containing diethyl ether (100 mL). The precipitate is collect, dissolved in CH2CI2 and re-precipitated
with diethyl ether. This procedure is repeated 3 additional times to afford the desired product.
The examples herein above encompass free radical moieties derived from 6-member ring starting materials. The disclosed compounds also encompass free radical moieties derived from 5-member ring starting materials, for example:
wherein Ri', R1", R1"', R2, L, L8, E, and X are further defined herein above. Such compounds, wherein are well known in the art as "Proxyl" compounds and many suitable precursors of the Proxyl "A" moiety are readily commercially available from standard suppliers of fine chemicals, such as Aldrich- Sigma of Milwaukee Wisconsin. For example, the following precursors of a Proxyl moiety are commercially available:
The preparation of compounds starting from such "Proxyl starting materials can be carried out in analogy to the procedures outlined in Schemes I and II above, and other similar procedures as would be well within the capabilities of one of ordinary skill in the art of synthetic organic chemistry.
Scheme VIII outlines an example of the preparation of compounds disclosed herein wherein the free radical moiety is derived from a 5-member ring starting material.
Scheme IX
11
Reagents and conditions: (a) 4-bromobutyryl chloride, CH2Cl2; rt, 48-72 hr.
11 12
Reagents and conditions: (b) P(C6Hj)3, dioxane; reflux, 72 hr.
EXAMPLE 6 ( {3-[4-(Triphenylphosphonium)butyrylamide]tnethyl-2,2,5,5-tetramethyl-pyrrolidinyloxy} free radical) bromide
Preparation of 3-(4-bromobutyrylamide)methyl-2,2,5,5-tetramethylpyrrolidin-yloxy, free radical (11): To a 250 mL 3-neck flask equipped with a reflux condenser and nitrogen inlet line is charge 3-aminomethyi-2,2,6,6-tetramethylpiperidine-l-oxyl, free radical [3- aminomethyl-proxyl] (3.42 g, 20 mmoϊ), tri ethyl amine (2.22 g, 22 mmol) and dry benzene (100 mL). The solution is cooled in an ice bath to O0C. 4-Bromobutyryl chloride (3.9 g, 21 mmol) is added slowly. After the addition is complete, the solution is allowed to warm to room temperature and stir over night. The contents of the reaction vessel is transferred to a separatory funnel and extracted with water (50 mL), brine (50 mL), then dried over Na2SO4. The solvent is removed in vacuo to afford the desired product which can be used for the next step without further purification.
Preparation of ( {3-[4-(triphenylphosphonium)butyrylamide]methyl -2,2,5,5- tetramethyl-pyrrolidinyloxy} free radical) bromide (12): To a 3-neck flask equipped with a reflux condenser and nitrogen inlet tube is charged 3-(4-bromobutyrylamide)methyl-2,2,5,5- tetramethylpyrrolidin-yloxy, free radical, 115 (6.68 g, 20 mmol) and dioxane (50 mL). The solution is stirred and triphenylphosphine (10.5 g, 40 mmol) is added. The mixture is then
brought to reflux for 24 hours. The reaction solution is cooled and the solvent removed under reduced pressure. The residue is treated with diethyl ether (200 mL), the organic layer is decanted and the residue dissolved in CH2Cl2 (10 mL) then added to a flask containing diethyl ether (100 mL). The precipitate is collect, dissolved in CH2Cl2 and re-precipitated with diethyl ether. This procedure is repeated 3 additional times to afford the desired product.
Another example of a related synthesis of compounds wherein Proxyl groups can be linked to phosphonium cations by ether groups derived from glycols, to form compounds within the scope of the invention is shown below in Scheme IX:
CH7-OH CH2-OH
-Pt-R1
Another example of a related synthesis of compounds wherein Proxyl groups can be linked to phosphonium cations by moieties derived from glycols, to form compounds within the scope of the invention is shown below in Scheme X:
n
O n
Those of ordinary skill in the art of synthetic chemistry can readily devise other related methods for synthesizing compound comprising Proxyl or Tempol antioxidant groups linked by various moieties to quaternary phosphonium or ammonium cations. Biological Activity of the Compounds
The salts described above have been found to be potent compounds in a number of in vitro biological assays that correlate to or are representative of human diseases, especially diseases of uncontrolled inflammation and/or cellular proliferation, including various cancers.
The biological activity of the compounds described herein can be measured, screened, and/or optimized by testing the salts for their relative ability to kill or inhibit the growth of various human tumor cell lines and primary tumor cell cultures.
Tumor cell lines that can be employed for such tests include, but are not limited to, known cell lines that model cancers and/or diseases of uncontrolled cellular proliferation, such as: • For Leukemia: CCRF-CEM, HL-60 (TB), K-562, MOLT-4, RPMI-8226, and SR.
Lung Cancer: A549/ATCC, EKVX, HOP-62, HOP-92, NCI-H226, NCI-H23, NCI-H322M, NCI-H460, and NCI-H522.
Colon Cancer: COLO 205, HCC-2998, HCT-1 16, HCT-15, HT-29, KM-12, and SW-
620.
CNS Cancer: SF-268, SF-295, SF-539, SNB- 19, SNB-75, U-231 , U-235 and U-251.
Melanoma: LOX-IMVI, MALME-3M, M-14, SK-MEL-2, SK-MEL-28, SK-MEL-5, UACC-257, and UACC-62. • Ovarian Cancer: IGR-OVI, OVC AR-3, OVC AR-4, OVC AR-5, OVC AR-8, and SK-
OV-3.
Renal Cancer: 786-0, A-498, ACHN, CAKI-I, RXF-393, RXF-631, SN12C, TK-IO, and UO-31.
Prostate Cancer: DU-145, PC-3 and LNCaP. • Breast Cancer: MDA-MB-468, MCF 7, MCF7/ADR-RES, MDA-MB-231/ATCC,
HS578T, MDA-MB-435, MDA-N, BT-549, and T-47D.
Pancreatic Cancer: PANC-I , Bx-PC3 AsPC-I .
After the compounds to be screened have been applied to one or more of the above cancer cell lines, the anti-cancer effectiveness can be gauged using a variety of assay procedures known to those of ordinary skill in the art for measuring the number of live cells in the cultures as a function of time.
One well known procedure employs 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide ("MTT") to differentiate live cells from dead cells. The MTT assay is based on the production of a dark blue formazan product by active dehydrogenase in the mitochondria of live tumor cells (see M. C. Alley, D. A. Scudiero, A. Monks, M. L.
Hursey, M. J. Czerwinski, D. L. Fine, B. J. Abbout, J. G. Mayo, R. H. Shoemaker and M. R. Boyd, Cancer Res., 48, 589, 1988). After exposure of cancer cells to the compounds to be screened for a fixed number of days, only living cells contain active dehydrogenases, and produce dark blue formazan from MTT and are stained. The numbers of live cells can be measured by absorbance of visible light by the formazan at 595 nm. Anti-cancer activity can be reported as percent of the tumor cell growth in a culture treated with a placebo. These MTT assay procedures have an advantage over an in vivo assay with common laboratory animals such as mice, in that results are obtained within a week as opposed to requiring several weeks or months. These MTT anti-cancer activity screening assay provides data regarding the general cytotoxicity of an individual compound. In particular, as described in the examples herein,
active anticancer compounds can be identified by applying the compounds at a concentration of about 10 μM to one or more cultured human tumor cell lines, such as for example leukemia, lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, or pancreatic cancer, so as to kill or inhibit cell growth of the tumor cells.
In some embodiments of the invention, the compounds of the invention are considered to be biologically active for the treatment of a particular cancer if, when they are applied to a culture of one of the above cancer cell lines at a concentration of about 10 μM or less, for a period of at least about 5 days, the growth of the cancer cells is inhibited, or the cancer cells killed to the extent of about 50% or more, as compared to a control not comprising the compound of the invention.
For DNA assay, each culture plate was thawed and equilibrated to room temperature under protection from light. Hoechst dye was then added to each well in 200 μL of high salt TNE buffer (10 mM Tris, ImM EDTA, 2 M NaCl [pH 7.4]) at a final concentration of 6.7 μg/mL. After further incubation at room temperature for 2 hours under protection from light, culture plates were scanned on the CytoFluor 2350™ scanner using the 360/460 nm filter excitation and emission set. The DNA fluorescence intensity was used as a measure of cell growth.
In particular, the biological activity of two particular salts whose structures are shown below were assayed for their relevance to the treatment or inhibition of the growth of prostate cancers.
n = 4 = "Mito-Tempol" = "MitoT"
n = 10 = "MitoT- 10"
The effects of varying concentrations of Mito-T drug on the growth of LNCaP and PC-3 cells over a period of 4 days was assayed using the Hoechst dye-DNA fluorescence assay described above. In these and all subsequent cell culture studies described below, each data point and its associated error bar are respectively, an average value and the standard deviation of data obtained from six wells of a 96-well plate run in duplicate in three separate sets of experiments.
The results are shown in Figure L Mito-T treatment inhibits the growth of both LNCaP and PC-3 cells, with estimated ICgo values of approximately 4 μM and 60 μM, respectively. The inhibitory effect of MitoT on the oxidative stress level in LNCaP prostate tumor cells can also be determined by the ratio of DCF fluorescence / Hoechst dye-DNA fluorescence (Ripple MO, Henry WF, Rago RP, Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst. 1997 Jan 1 ;89(l):40-8) . DCFH is oxidized to DCF by ROS to yield easily quantifiable ROS levels monitored by the green fluorescence of the DCF (6-carboxy-2r,7'-dichlorofiuorescin diacetate) dye, as can be seen in Figure 2. The DCF fluorescence in LNCaP cells treated with 1 nM of the androgen analog R1881 and normalized with the blue fluorescence of the Hoechst dye-DNA complex in the same cells at varying concentrations of MitoT in order to evaluate the level the oxidative stress per individual cell. The inhibitory effect of MitoT on the oxidative stress level in LNCaP prostate tumor cells can be determined by the ratio of DCF fluorescence/Hoechst dye-DNA fluorescence. MitoT treatment markedly reduced the oxidative stress in LNCaP cells as determined by DCF fluorescence/DNA fluorescence assay shown in Figure 3. MitoT treatment effectively and reproducibly reduced the ROS levels in LNCaP cells at concentrations at or above about 1-10 μM. It should be noted that MitoT treatment induced a reduction of oxidative stress determined by DCF assay and mitochondrial function determined by MTT assay, and is parallel to MitoT's effect in the inhibition of prostate tumor cell growth as determined by DNA assay, as shown in Fig. 4, This oxidative stress is probably due to increased lipid peroxidation during apoptotic and/or necrotic cell death (reviewed in 1,2). Results shown in Figure 5 clearly demonstrates that MitoT pretreatment at a sublethal dose (1 μM) can also completely block the oxidative stress induced by androgen (Rl 881) treatment in LNCaP cells. As most published literature demonstrates that androgen is the
leading cause of oxidative stress generation and changes (Reviewed by Attia S and Wilding G, Novel Antioxidant Technology for Prostate Cancer Chemoprevention and Treatment. Expert opinion on therapeutic patents, 16(9) 1255-67), which is a primary causative agent of prostate cancer and other prostatic diseases, including, but not limited, to benign prostatic hyperplasia. Thus, the anti-oxidant spin trapping effect of MitoT treatment is capable of removing one of the most important metabolic products that causes cancer in general and prostate cancer for specific.
Figure 6 shows that when animals are treated with MitoT, the serum level of MitoT within the first hour of treatment is between 10-20 μg/ml, which is 10 - 20 times above the level of MitoT required to block androgen induced oxidative stress in LNCaP cells (Fig. 5) and in the concentration range of completely blocking all oxidative stress in the cancer cells. Also, under these treatment conditions, MitoT markedly reduced the oxidative stress in the prostatic lumen of live animals, as observed by Hydroethidine dye oxidation assay in the animal's prostate. Hydroethidine dye was injected into the tail vein of male mice one hour before sacrifice. Hydroethidine shows a typical red fluorescence upon oxidation by ROS. The resected prostate glands of the sacrificed animals were processed and observed under fluorescence microscopy. The data are shown in Figure 7. As in the case of cell culture studies, the MitoT treated animals did not show any evidence of oxidative stress in the prostate gland Using the Compositions
In view of their ability to inhibit the growth of, at least some cancer cell lines in vitro, the compounds described herein can be used to prevent, alleviate or otherwise treat diseases of uncontrolled proliferation in mammals, including humans, such as cancer or precancerous diseases. The compounds described herein can be used for the preparation of medicaments for treating diseases of uncontrolled inflammation, proliferation, cancers, and prostate cancer.
Therefore, in some embodiments, the invention relates to methods of treatment for a disease of uncontrolled cellular inflammation, proliferation, wherein the method comprises administering to a mammal diagnosed as having a disease of uncontrolled cellular inflammation and/or proliferation a compound of the invention or a pharmaceutical composition thereof comprising one or more of the compounds of the invention, in an amount that is effective to treat the disease of uncontrolled cellular inflammation and/or proliferation.
The disease of uncontrolled cellular inflammation and/or proliferation treated can be a
hyperplasia or a carcinoma, lymphoma, leukemia, or sarcoma. The types of diseases treated by methods of the invention include but are not limited to Hodgkin's Disease, myeloid leukemia, polycystic kidney disease, bladder cancer, brain cancer, head and neck cancer, kidney cancer, lung cancer, myeloma, neuroblastoma, glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, colon cancer, cervical carcinoma, breast cancer, metastases to the brain or bone, epithelial cancer, and leukemia. The compositions can also be used as regulators in diseases of uncontrolled inflammation and/or proliferation and/or precancerous conditions such as cervical and anal dysplasias, other dysplasias, severe dysplasias, hyperplasias, atypical hyperplasias, and neoplasias. The compounds of the invention have been found to particularly effective for the treatment of prostate cancers and related neoplasias, including pancreas adenocarcinomas or prostate adenocarcinomas, and/or inhibiting the growth of prostate hyperplasias (noncancerous) and/or cancers and related neoplasias.
Methods Of Treating Diseases With The Salts And/Or Compositions In some embodiments, the inventions described herein relate to methods for treating or inhibiting the recurrence, progression or metastasis, of a cancer or a neoplasia precursor thereof, consisting of administering to a mammal diagnosed as having a cancer or precursor neoplasia thereof, in an amount effective to treat the cancer or inhibit the recurrence, progression, or metastasis of the cancer or precursor neoplasia thereof, one or more pharmaceutically acceptable salts having a cation having the formula
R1"' I © L b K ]
R 1' wherein a) A is an antioxidant moiety comprising one or more nitroxide or hydroxylamine moieties, or a prodrug thereof, having from three to 16 carbon atoms, b) L is an organic linking moiety comprising 4 to 30 carbon atoms, c) E is a nitrogen or phosphorus atom, d) Ri', Ri", and R1'" are each independently selected organic moieties comprising between 1 and 12 carbon atoms, wherein E, Rs', Ri", and R1'" together form a quaternary ammonium or
phosphonium cation ; and wherein the salt farther comprises is one or more pharmaceutically acceptable anions Xm~, wherein m is an integer from 1 to 4, in sufficient amount to form the pharmaceutically acceptable salt. The pharmaceutically acceptable salts of the invention have been found to be particularly effective in treating certain forms inflammation, organ enlargement or cancer, including, but not limited to prostate hyperplasia and/or cancer, colorectal cancer, gastric cancer, renal cancer, skin cancer, head and neck cancer, brain cancer, pancreatic cancer, lung cancer, ovarian cancer, uterine cancer, liver cancer, and breast cancer. In some embodiments, the invention relates to method for treating, or inhibiting inflammation and benign prostatic hyperplasia or the occurrence, recurrence, progression or metastasis of prostate cancer, consisting of administering to a mammal diagnosed as having prostate disease or cancer or hyperplasia or precursor neoplasia thereof, in an amount effective to treat the disease or cancer or inhibit the occurrence, recurrence, progression, or metastasis of the prostate disease or cancer or precursor neoplasia thereof, one or more pharmaceutically acceptable salts of the invention comprising a cation of Formula (I). In some favored embodiments of the invention, the pharmaceutically acceptable salts have a cation having the formula:
wherein e) E is a nitrogen or phosphorus atom, f) Ri', Ri", and Ri'" are each independently selected organic moieties comprising between 1 and 12 carbon atoms, g) n is an integer between 8 and 12, and wherein E, Ri ' , Ri " , and Rj " ' together form a quaternary ammonium or phosphonium cation ; and the salt also comprises one or more pharmaceutically acceptable anions Xm" wherein m is an integer from 1 to 4, sufficient to form the pharmaceutically acceptable salt.
Preparing And Administering The Compounds And Compositions As Pharmaceutical Compositions
Although the compounds described herein can be administered as pure chemicals either singularly or p rurally, it is preferable to present the active ingredient as a pharmaceutical composition. Thus, another embodiment of the invention is the use of a pharmaceutical composition comprising one or more compounds and/or a pharmaceutically acceptable salt thereof, together with one or more pharmaceutically acceptable carriers thereof and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) should be "acceptable" in the sense of being compatible with the other ingredients of the composition and not overly deleterious to the recipient thereof. The pharmaceutical composition, is administered to an animal diagnosed as in need of treatment for a disease of uncontrolled cellular inflammation and/or proliferation, in an amount effective to treat the disease of uncontrolled cellular inflammation and/or proliferation, such as the various cancers and precancerous conditions described herein. As used herein, "pharmaceutical composition" means therapeutically effective amounts of a pharmaceutically effective compound together with suitable combination of one or more pharmaceutically-acceptable carriers, many of which are known in the art, including diluents, preservatives, solubilizers, emulsifiers, and adjuvants, collectively".
As used herein, the terms "effective amount" and "therapeutically effective amount" refer to the quantity of active therapeutic agent sufficient to yield a desired therapeutic response, without undue adverse side effects, such as toxicity, irritation, or allergic response. The specific "effective amount" will, obviously, vary with such factors as the particular condition being treated, the physical condition of the patient, the type of animal being treated, the duration of the treatment, the nature of concurrent therapy (if any), and the specific formulations employed and the structure of the compounds or its derivatives. In this case, an amount would be deemed therapeutically effective if it resulted in one or more of the following: (a) the prevention of an androgen-mediated or androgen-independent disorder (e. g. , prostate cancer); and (b) the reversal or stabilization of an androgen-mediated or androgen-independent disorder (e. g., prostate disease and cancer). The optimum effective amounts can be readily determined by one of ordinary skill in the art using routine experimentation .
Pharmaceutical compositions can be liquids or lyophilized or otherwise dried
formulations and include diluents of various buffer content (e. g.,Tris-HCI, acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e. g., Tween 20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents (e. g., glycerol, polyethylene glycerol), anti-oxidants (e. g., ascorbic acid, sodium metabisulfite), preservatives (e. g., Thiomersal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e. g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the protein, complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, gels, hydrogels, etc, or onto liposomes, microemulsions, micelles, etc. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's and fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on
Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, collating agents, inert gases and the like.
Controlled or sustained release compositions administrable according to the invention include formulation in lipophilic depots (e. g. fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e. g. poloxamers or poloxamines) and the compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to Hgands of tissue-specific receptors.
Other embodiments of the compositions administered according to the invention incorporate particulate forms, protective coatings, protease inhibitors or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral.
Compounds modified by the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline are known to exhibit substantially longer half-lives in blood following intravenous injection than do the corresponding modified compounds (Abuchowski et al. , 1981; Newmark et al. , 1982; and Katre et al. , 1987). Such modifications may also increase the compound's solubility in
aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the compound, and greatly reduce the immunogenicity and reactivity of the compound. As a result, the desired in vivo biological activity may be achieved by the administration of such polymer-compound abducts less frequently or in lower doses than with the unmodified compound.
In yet another method according to the invention, a pharmaceutical composition can be delivered in a controlled release system. For example, the agent may be administered using intravenous infusion, an implantable osmotic pump, a transdermal patch, liposomes, or other modes of administration. In one embodiment, a pump may be used (see Langer, supra; Sefton, CRC Crit Ref. Biomed. Eng. 14: 201 (1987); Buchwald et al., Surgery 88: 507
(1980); Saudek et al., N. Engl. J. Med. 321 : 574 (1989). In another embodiment, polymeric materials can be used. In yet another embodiment, a controlled release system can be placed in proximity to the therapeutic target, i. e., the prostate, thus requiring only a fraction of the systemic dose (see, e. g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984). Other controlled release systems are discussed in the review by Langer (Science 249: 1527-1533 (1990).
The pharmaceutical preparation can comprise the anti-androgen compound alone, or can further include a pharmaceutically acceptable carrier, and can be in solid or liquid form such as tablets, powders, capsules, pellets, solutions, suspensions, elixirs, emulsions, gels, creams, or suppositories, including rectal and urethral suppositories.
Pharmaceutically acceptable carriers include gums, starches, sugars, cellulosic materials, and mixtures thereof. The pharmaceutical preparation containing the anti-androgen compound can be administered to a patient by, for example, subcutaneous implantation of a pellet. In a further embodiment, a pellet provides for controlled release of anti-androgen compound over a period of time. The preparation can also be administered by intravenous, intra-arterial, or intramuscular injection of a liquid preparation oral administration of a liquid or solid preparation, or by topical application. Administration can also be accomplished by use of a rectal suppository or a urethral suppository.
Though it is not possible to specify a single predetermined pharmaceutically effective amount of the compounds of the invention, and/or their pharmaceutical compositions, for each and every disease condition to be treated, determining such pharmaceutically effective amounts are within the skill of, and ultimately at the discretion of an attendant physician or
clinician of ordinary skill. In some embodiments, the active compounds of the invention are administered to achieve peak plasma concentrations of the active compound of from typically about 0.1 to about 100 μM, about 1 to 50 μM, or about 2 to about 30 μM. This can be achieved, for example, by the intravenous injection of a 0.05% to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 0.5-500 mg of the active ingredient. Desirable blood levels can be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the active compounds of the invention.
Pharmaceutical compositions include those suitable for oral, enteral, parental (including intramuscular, subcutaneous and intravenous), topical, nasal, vaginal, ophthalinϊcal, sublingual, nasal or by inhalation administration. The compositions can, where appropriate, be conveniently presented in discrete unit dosage forms and can be prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active compound with liquid carriers, solid matrices, semi-solid carriers, finely divided solid carriers or combination thereof, and then, if necessary, shaping the product into the desired delivery system.
The compounds of the invention can have oral bioavailability as exhibited by blood levels after oral dosing, either alone or in the presence of an excipient. Oral bioavailability allows oral dosing for use in chronic diseases, with the advantage of self-administration and decreased cost over other means of administration. Pharmaceutical compositions suitable for oral administration can be presented as discrete unit dosage forms such as hard or soft gelatin capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or as granules; as a solution, a suspension or as an emulsion. The active ingredient can also be presented as a bolus, electuary or paste. Tablets and capsules for oral administration can contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents. The tablets can be coated according to methods well known in the art., e.g., with enteric coatings.
Oral liquid preparations can be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or can be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which can include edible oils), or one or more preservative.
The pharmaceutical preparations administrable by the invention can be prepared by known dissolving, mixing, granulating, or tablet-forming processes. For oral administration, the compounds or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are mixed with additives customary for this purpose, such as vehicles, stabilizers, or inert diluents, and converted by customary methods into suitable forms for administration, such as tablets, coated tablets, hard or soft gelatin capsules, aqueous, alcoholic or oily solutions. Examples of suitable inert vehicles are conventional tablet bases such as lactose, sucrose, or cornstarch in combination with binders such as acacia, cornstarch, gelatin, with disintegrating agents such as cornstarch, potato starch, alginic acid, or with a lubricant such as stearic acid or magnesium stearate.
Examples of suitable oily vehicles or solvents are vegetable or animal oils such as sunflower oil or fish-liver oil. Preparations can be effected both as dry and as wet granules or supercritically formulated nanoparticles.
The compounds can also be formulated for parenteral administration (e.g., by injection, for example, bolus injection or continuous infusion) and can be presented in unit dose form in ampules, pre-filled syringes, small bolus infusion containers or in multi-does containers with an added preservative. The compositions can take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient can be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
For parenteral administration (subcutaneous, intravenous, intraarterial, or intramuscular injection), the compounds or their physiologically tolerated derivatives such as salts, esters, N-oxides, and the like are converted into a solution, suspension, or expulsion, if desired with the substances customary and suitable for this purpose, for example, solubilizers or other auxiliaries. Examples are sterile liquids such as water and oils, with or without the addition of a surfactant and other pharmaceutically acceptable adjuvants. Illustrative oils are those of petroleum, animal, vegetable, or synthetic origin, for example, peanut oil, soybean oil, or mineral oil. In general, water, saline, aqueous dextrose and related sugar solutions, and glycols such as propylene glycols or polyethylene glycol are preferred liquid carriers, particularly for injectable solutions.
The preparation of pharmaceutical compositions which contain an active component
is well understood in the art. Such compositions may be prepared as aerosols delivered to the nasopharynx or as injectables, either as liquid solutions or suspensions; however, solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The preparation can also be emulsified. The active therapeutic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like or any combination thereof.
In addition, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents which enhance the effectiveness of the active ingredient.
The compounds of the invention comprise cationic anti-oxidants in the form pharmaceutically acceptable salt with pharmaceutically acceptable anions. Pharmaceutically acceptable salts include pharmaceutically acceptable halides such as fluoride, chloride, bromide, or iodide, tribasic phosphate, dibasic hydrogen phosphate, monobasic dihydrogen phosphate, or the anionic forms of pharmaceutically acceptable organic carboxylic acids as acetates, oxalates, tatrates, mandelates, succinates, citrates, and the like. Such pharmaceutically acceptable salts can be readily synthesizes from other salts used for the initial synthesis of the compounds by ion exchange reactions and technologies well known to those of ordinary skill in the art. Salts formed from any free carboxyl groups on the cationic antioxidant moieties can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases asisopropylamine, trimethylamine, 2- ethylamino ethanol, histidine, procaine, and the like.
For use in medicine, the salts of the anti-androgen compound may be pharmaceutically acceptable salts. Other salts may, however, be useful in the commercial or laboratory preparation of the compounds according to the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
In addition, the salts described herein may be provided in the form of nutraceutical compositions where the anti-oxidant properties of the salts prevents the onset of or reduces or stabilizes various disorders, e.g., including inhibiting the occurrence of various forms of cancer, including prostate cancer. The term "nutraceutical," or "nutraceutical composition," for the purposes of this specification, refers to a food item, or a part of a food item, that offers medical health benefits, including prevention and/or treatment of disease. A nutraceutical composition according to the present invention may contain only a cationic antioxidant compound according to the present invention as an active ingredient or, alternatively, may further comprise, in admixture with the aforesaid cationic antioxidant compound, dietary supplements including vitamins, co-enzymes, minerals, herbs, amino acids and the like which supplement the diet by increasing the total intake of that substance.
Therefore, the present invention provides methods of providing nutraceutical benefits to a patient, comprising the step of administering to the patient a nutraceutical composition containing a compound having Formula I or a pharmaceutically acceptable salt thereof. Such compositions generally include a "nutraceutically-acceptable carrier" which, as referred to herein, is any carrier suitable for oral delivery including, but not limited to, the aforementioned pharmaceutically-acceptable carriers. In certain embodiments, nutraceutical compositions according to the invention comprise dietary supplements which, defined on a functional basis, include immune boosting agents, anti-inflammatory agents, anti-oxidant agents, or mixtures thereof.
Although some of the supplements listed above have been described as to their pharmacological effects, other supplements may also be utilized in the present invention and their effects are well documented in the scientific literature.
In general, one of skill in the art understands how to extrapolate in vivo data obtained in a model organism, such as athymic nude mice inoculated with human tumor cell lines, to another mammal, such as a human. These extrapolations are not simply based on the weights of the two organisms, but rather incorporate differences in rates of metabolism, differences in pharmacological delivery, and administrative routes. Based on these types of considerations, a suitable dose will, in alternative embodiments, typically be in the range of from about 0.5 to about 10 mg/kg/day, or from about 1 to about 20 mg/kg of body weight per day, or from about 5 to about 50 mg/kg/day.
The desired dose can conveniently be presented in a single dose or as divided doses
administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose, as necessary by one skilled in the art, can itself be further divided, e.g., into a number of discrete loosely spaced administrations.
One skilled in the art will recognize that dosage and dosage forms outside these typical ranges can be tested and, where appropriate, be used in the methods of this invention.
Combinations with Other Active Agents
According to another aspect of the invention, pharmaceutical compositions of matter useful for the treatment of cancer and/or benign prostatic hyperplasia are provided that contain, in addition to the aforementioned compounds, an additional therapeutic agent. Such agents can be chemotherapeutic agents, ablation or other therapeutic hormones, antineoplastic agents, monoclonal antibodies useful against cancers and angiogenesis inhibitors. The following discussion highlights some agents in this respect, which are illustrative, not limitative. A wide variety of other effective agents also can be used.
Among hormones which can be used in combination with the present inventive compounds, diethylstilbestrol (DES), leuprolide, flutamϊde, hydroxyflutamide, bicalutamide, cyproterone acetate, ketoconazole, abiraterone acetate and amino glutethimide.
Among antineoplastic and anticancer agents that can be used in combination with the inventive compounds, 5-fluorouracil, vinblastine sulfate, estramustine phosphate, suramin and strontium-89. Other chemotherapeutics useful in combination and within the scope of the present invention are buserelin, chlorotranisene, chromic phosphate, cisplatin, cyclophosphamide, dexamethasone, doxorubicin, estradiol, estradiol valerate, estrogens conjugated and esterified, estrone, ethinyl estradiol, floxuridine, goserelin, hydroxyurea, melphalan, methotrexate, mitomycin and prednisone.
It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
Claims
1. A method for treating or inhibiting the occurrence, recurrence, progression or metastasis, of a cancer or a neoplasia precursor thereof, consisting of administering to a mammal diagnosed as having a cancer or precursor neoplasia thereof, in an amount effective to treat the cancer or neoplasia precursor thereof or inhibit the occurrence, recurrence, progression, or metastasis of the cancer or precursor neoplasia thereof, one or more pharmaceutically acceptable salts having one or more cation having the formula:
R1"' I ©
A L E R1"
wherein a) A is an antioxidant moiety comprising one or more nitroxide or hydroxylamine moieties, or a prodrug thereof, having from three to 16 carbon atoms, b) L is an organic linking moiety comprising 4 to 30 carbon atoms, c) E is a nitrogen or phosphorus atom, d) R1', Ri", and R1'" are each independently selected organic moieties comprising between 1 and 12 carbon atoms, wherein E, Rj', Ri", and Ri'" together form a quaternary ammonium or phosphonium cation ; and wherein the salt further comprises is one or more pharmaceutically acceptable anions Xm~, wherein m is an integer from 1 to 4, in sufficient amount to form the pharmaceutically acceptable salt.
2. The method of claim 1 , wherein A comprises a moiety having the structure
wherein the R2 moieties are independently selected from CrC4 alkyls and Lg is a bridging atom or moiety selected from -CH2-, -O-, -CH2-O-, -CH2-NH-, -C(O)O-, -
C(O)NH-, -NH-, or -NR3-, wherein R3 is a Ci-C4 alkyl;
L comprises a polyalkylene chain having 4 to 30 carbon chain atoms, wherein any one or more of the hydrogens bonded to said carbon chain atoms can be optionally substituted with one or two independently selected hydroxyl, halogen, amino, methylamino, dimethylamino, or C1-C4 organic moieties selected from alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties; and
Ri', Rj", and R1'" are each independently selected from alkyl, aryl, heteroaryl, or aralkyl moieties optionally substituted with one or two independently selected hydroxyl, halogen, amino, amino, cyano, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties.
3. The method of claim 1 , wherein A comprises a moiety having the structure
wherein Lg is a bridging atom or moiety selected from -CH2-, -O-, -CH2-O-, -CH2- NH-, -C(O)O-, -C(O)NH-, -NH-, or -NR3-, wherein R3 is a Ci-C4 alkyl.
4. The method of claim 2, wherein L has 4 to 24 carbon chain atoms.
5. The method of claim 4, wherein L has 5 to 16 carbon chain atoms.
6. The method of claim 5, wherein L has 8 to 12 carbon chain atoms.
7. The method of claim 6, wherein L has 10 carbon chain atoms.
8. The method of claim 1 , wherein L comprises a polymethylene chain having 4 to 30 carbon chain atoms.
9. The method of claim 8, wherein L comprises a polymethylene chain having 4 to 24 carbon chain atoms.
10. The method of claim 9, wherein L comprises a polymethylene chain having 8 to 16 carbon chain atoms.
1 1. The method of claim 10, wherein L has 10 carbon chain atoms.
12. The method of claim 2, wherein L further comprises, in the polyalkylene, one to 10 groups independently selected from -O-, -S-, -S(O)-, -S(O)2-,-NH-, -NCH3-, -C(O)-, Or -CO2-.
13. The method of claim 2, wherein R1', Ri", and Ri'" are each independently selected from alkyl aryl, or benzyl moieties optionally substituted with one or two independently selected hydroxyl, halogen, amino, amino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties.
14. The method of claim 13, wherein R1', R1", and R1'" are independently selected from C4-C io alkyl or phenyl moieties optionally substituted with one or two independently selected hydroxyl, halogen, amino, cyano, methylamino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties.
15. The method of claim 14, wherein R1', R1", and R1"' are independently selected from C4-CjO alkyl or phenyl moieties.
16. The method of claim 15, wherein R1', R1", and R1"' are R-C4H9 moieties.
17. The method of claim 15, wherein R!', R1", and R1'" are phenyl moieties.
18. The method of claim 13, wherein R1', R1", and R1'" are benzyl moieties.
19. The method of claim 2, wherein E is a nitrogen atom.
20. The method of claim 19, wherein R1', R1", and R1'" are independently selected from C4-C10 alkyl or phenyl moieties.
21. The method of claim 2, wherein E is a phosphorus atom.
22. The method of claim 21, wherein R1', R1", and R1'" are independently selected from C4-CiO alkyl or phenyl moieties optionally substituted with one or two independently selected hydroxyl, halogen, amino, amino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties.
23. The method of claim 22, wherein R1', R1", and R1'" are independently selected from C4-C10 alkyl or phenyl moieties.
24. The method of claim 23, wherein R1', R1", and R1'" are phenyl moieties.
25. The method of claim 1 , wherein X™~ is a halide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogen phosphate, carbonate, hydrogen carbonate, fumarate, maleate, maltolate, succinate, acetate, benzoate, oxalate, citrate, or tartrate anion.
26. The method of claim 25, wherein Xm" is a halide anion.
27. The method of claim 26, wherein Xm~ is a bromide anion.
28. The method of claim 1 , wherein the cancer is prostate, breast, uterine, colon, gastric, rectal, skin, brain, head and neck, ovarian, renal, bladder or pancreatic cancer, leukemia, or melanoma.
29. The method of claim 28, wherein the cancer is breast cancer or prostate cancer.
30. The method of claim 29, wherein the cancer is prostate cancer and A has the structure
31. The method of claim 30, wherein A has the structure
32. The method of claim 30, wherein L comprises a polymethylene chain having 8 to 12 carbon chain atoms.
33. The method of claim 30, wherein L has the formula -(CH2JiO-.
34. The method of claim 30, wherein E is a nitrogen atom.
35. The method of claim 33, wherein R1', R1", and R1'" are independently selected from C4-CjO alkyl or phenyl moieties optionally substituted with one or two independently selected hydroxyl, halogen, amino, amino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties.
36. The method of claim 29, wherein E is a phosphorus atom.
37. The method of claim 36, wherein R1', R1", and R1"' are independently selected from C4-C1Q alkyl or phenyl moieties optionally substituted with one or two independently selected hydroxyl, halogen, amino, amino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties.
38. The method of claim 37, wherein R1', R1", and R1"' are phenyl moieties.
39. The method of claim 29, wherein the cancer is prostate cancer and A is a moiety having the structure
40. The method of claim 39, wherein a) A is a moiety having the structure
b) L is a polymethylene chain having 4 to 12 carbon chain atoms, c) E is a phosphorus atom, and d) R1', R1", and R1'" are independently selected from C4-CiO alkyls or phenyl moieties optionally substituted with one or two hydroxyl, halogen, amino, amino, dimethylamino, alkyl, hydroxymethyl, methoxy, methoxylmethyl, carboxy, or carboxymethyl moieties.
41. The method of claim 40, wherein the cation has the formula wherein n is an integer etween 4 and 12. ph
42. The method of claim 41 , wherein n is an integer between 8 and 12.
43. The method of claim 42, wherein n is 10.
44. A method for treating, or inhibiting the occurrence, recurrence, progression or metastasis of prostate cancer, comprising administering to a mammal diagnosed as having prostate cancer or precursor neoplasia thereof, in an amount effective to treat the cancer or inhibit the occurrence, recurrence, progression, or metastasis of the prostate cancer or precursor neoplasia thereof, one or more pharmaceutically acceptable salts having a cation having the formula:
wherein a) E is a nitrogen or phosphorus atom, b) Rj ', R1 ", and R1 '" are each independently selected organic moieties comprising between 1 and 12 carbon atoms, c) n is an integer between 8 and 12, and wherein E, Ri', Rj", and R1 1" together form a quaternary ammonium or phosphonium cation ; and the salt also comprises one or more pharmaceutically acceptable anions Xm~ wherein m is an integer from 1 to 4, sufficient to form the pharmaceutically acceptable salt.
45. The method of claim 44, wherein a) E is a phosphorus atom and b) Rj', R1", and R1'" are independently selected from C4-Ci0 alkyl or phenyl moieties optionally substituted with one or two hydroxyl, halogen, amino, amino, dimethylamino, alkyl, hydroxyalkyl, alkoxy, alkoxylalkyl, carboxy, or carboxyalkyl moieties, and c) Xm~ is a halide anion.
46. The method of claim 45, wherein a) E is a phosphorus atom and b) R1', R1", and R1" ' are phenyl moieties, and c) Xm~ is a bromide anion.
47. A salt comprising one or more cations having the formula
or or
wherein a) E is a nitrogen or phosphorus atom, b) Ri ' , Ri " , and Ri ' " are each independently selected organic moieties comprising between 1 and 12 carbon atoms, c) n is an integer between 5 and 24, and wherein E, Rj', R]", and Rf" together form a quaternary ammonium or phosphonram cation ; and the organic salt also comprises one or more anions Xm~ wherein m is an integer from 1 to 4, to form the organic salt.
48. The salt of claim 47, wherein E is a phosphorus atom.
49. The salt of claim 47, wherein n is an integer between 8 and 12.
50. The salt of claim 49, wherein n is 10.
51. The salt of claim 47, wherein R1', R1", and R1'" are independently selected from C1- Cio alkyl or phenyl moieties.
52. The salt of claim 51, wherein R1', R1", and R1'" are independently selected from C4- Cio alkyl or phenyl moieties.
53. The salt of claim 52, wherein R1', R1", and R1'" are phenyl moieties.
54. The salt of claim 47, wherein Xm~ is a pharmaceutically acceptable anion.
55. A pharmaceutical composition comprising one or more pharmaceutically acceptable salts of claim 47 and one or more pharmaceutically acceptable carriers.
56. A method for treating, or inhibiting the occurrence, recurrence, progression or metastasis of prostate cancer, comprising administering to a mammal diagnosed as having prostate cancer or precursor neoplasia thereof, in an amount effective to treat the cancer or inhibit the occurrence, recurrence, progression, or metastasis of the prostate cancer or precursor neoplasia thereof, one or more pharmaceutically acceptable salts of claim 47.
57. An organic salt comprising one or more cations having the formula
or or
or or
wherein a) E is a nitrogen or phosphorus atom, b) Ri ' j R] ", and Ri "' are each independently selected organic moieties comprising between 1 and 12 carbon atoms, c) n is an integer between 5 and 24, and wherein E, Rj', Rf, and Ri'" together form a quaternary ammonium or phosphonium cation ; and wherein the organic salt also comprises one or more anions Xra" wherein m is an integer from 1 to 4, to form the organic salt.
58. The organic salt of claim 57, wherein E is a phosphorus atom.
59. The organic salt of claim 58, wherein R1', R1", and R1'" are independently selected from Ci-Cio alkyl or phenyl moieties.
60. The organic salt of claim 59, wherein R1', R!", and R1'" are independently selected from C4-C10 alkyl or phenyl moieties.
61. The organic salt of claim 60, wherein R1', R1", and R1'" are phenyl moieties.
62. The organic salt of claim 57, wherein Xm~ is a pharmaceutically acceptable anion.
63. A pharmaceutical composition comprising one or more pharmaceutically acceptable salts of claim 57 and one or more pharmaceutically acceptable carriers.
64. A method for treating, or inhibiting the recurrence, progression or metastasis of prostate cancer, consisting of administering to a mammal diagnosed as having prostate cancer or precursor neoplasia thereof, in an amount effective to treat the cancer or inhibit the recurrence, progression, or metastasis of the prostate cancer or precursor neoplasia thereof, one or more pharmaceutically acceptable salts of claim 57.
65. A method for treating or inhibiting the occurrence, recurrence, or progression of a non-cancerous hyperplasia, comprising administering to a mammal diagnosed as having a non-cancerous hyperplasia, in an amount effective to treat the non-cancerous hyperplasia or inhibit the occurrence, recurrence, or progression of the non-cancerous hyperplasia, one or more pharmaceutically acceptable salts having one or more cation having the formula:
R1-
E I θ R1"
R1 1 wherein a) A is an antioxidant moiety comprising one or more nitroxide or hydroxylamine moieties, or a prodrug thereof, having from three to 16 carbon atoms, b) L is an organic linking moiety comprising 4 to 30 carbon atoms, c) E is a nitrogen or phosphorus atom, d) Ri ', Ri ", and Rj ' " are each independently selected organic moieties comprising between 1 and 12 carbon atoms, wherein E, Rj', R|", and Ri'" together form a quaternary ammonium or phosphonium cation ; and wherein the salt further comprises is one or more pharmaceutically acceptable anions Xm\ wherein m is an integer from 1 to 4. in sufficient amount to form the pharmaceutically acceptable salt.
- 68 -
RECΪ.HΞD SHEET {RULE 'M) ISA/EP
66. The method of claim 65, wherein the non-cancerous hyperplasia is prostate hyperplasia.
- 69 -
10932964.1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90523707P | 2007-03-06 | 2007-03-06 | |
PCT/US2008/056035 WO2008109740A2 (en) | 2007-03-06 | 2008-03-06 | Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2139522A2 true EP2139522A2 (en) | 2010-01-06 |
Family
ID=39591290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08731532A Withdrawn EP2139522A2 (en) | 2007-03-06 | 2008-03-06 | Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2139522A2 (en) |
WO (1) | WO2008109740A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
US8853277B2 (en) | 2009-11-30 | 2014-10-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC) |
JP5780497B2 (en) * | 2011-03-10 | 2015-09-16 | 国立大学法人京都大学 | Amphiphilic compound having stable radical structure, surfactant using the amphiphilic compound, micelle using the amphiphilic compound, and emulsion using the amphiphilic compound |
WO2016025725A1 (en) * | 2014-08-14 | 2016-02-18 | The Medical College Of Wisconsin, Inc. | Modified mito-metformin compounds and methods of synthesis and use thereof |
US20180028521A1 (en) | 2016-07-29 | 2018-02-01 | Janssen Pharmaceutica Nv | Methods of Treating Prostate Cancer |
WO2022164901A1 (en) * | 2021-01-26 | 2022-08-04 | The Medical College Of Wisconsin, Inc. | Enhanced anti-proliferative and antitumor immune effects of mitochondria-targeted hydroxyurea |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0986393T3 (en) * | 1997-05-27 | 2004-07-05 | Us Gov Health & Human Serv | Use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer |
WO2000000157A2 (en) * | 1998-06-26 | 2000-01-06 | Georgetown University Medical Center | Use of tempo and tempo derivatives for inducing cell death |
JP4566519B2 (en) * | 2003-02-28 | 2010-10-20 | 大塚化学株式会社 | Water-soluble N-oxyl compound, oxidation catalyst and method for producing oxide using the same |
-
2008
- 2008-03-06 EP EP08731532A patent/EP2139522A2/en not_active Withdrawn
- 2008-03-06 WO PCT/US2008/056035 patent/WO2008109740A2/en active Application Filing
Non-Patent Citations (1)
Title |
---|
JANEZ MRAVLJAK ET AL: "Synthesis and Biological Evaluation of Spin-Labeled Alkylphospholipid Analogs", JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, no. 20, 1 October 2005 (2005-10-01), pages 6393 - 6399, XP055012330, ISSN: 0022-2623, DOI: 10.1021/jm050189v * |
Also Published As
Publication number | Publication date |
---|---|
WO2008109740A2 (en) | 2008-09-12 |
WO2008109740A3 (en) | 2008-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20130338110A1 (en) | Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers | |
EP2139522A2 (en) | Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers | |
JP2010159274A (en) | Muscarinic receptor agonist | |
KR100674813B1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
KR101260717B1 (en) | tubulin inhibitors | |
KR20210006364A (en) | Target proteolytic compounds, their anti-tumor applications, their intermediates and applications of intermediates | |
US20030195360A1 (en) | Indolyl-3-glyoxylic acid derivatives having antitumor action | |
SG175251A1 (en) | Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses | |
WO2006057448A1 (en) | Arylalkanoic acid derivative | |
US20070244110A1 (en) | Treatment of prostate cancer, melanoma or hepatic cancer | |
EP2776407A1 (en) | Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto | |
EP2106399A2 (en) | Imidazole derivatives as kinesin spindle protein inhibitors (eg-5) | |
CA3082735A1 (en) | Substituted macrocyclic indole derivatives | |
KR20050085542A (en) | Pyrazine-based tubulin inhibitors | |
KR20190115451A (en) | Anti-fibrous compound | |
EP2709998B1 (en) | Substituted indole derivatives for the treatment of immunological disorders | |
CN113348165A (en) | 1,2, 4-triazin-3 (2H) -one compounds for the treatment of hyperproliferative diseases | |
CA2891900C (en) | Derivatives of indole for the treatment of cancer, viral infections and lung diseases | |
JP3588363B2 (en) | Quinoxaline diones | |
DE60006990T2 (en) | PYRROL DERIVATIVES WITH ANTIPROLIFERATIVE EFFECT SUITABLE FOR THE TREATMENT OF CANCER | |
SG177462A1 (en) | Fluorinated derivatives of 3-hydroxypyridin-4-ones | |
EP3976606A1 (en) | Crystalline polymorphs of a 1-thiazol-2-yl-pyrazole-5-carboxylic acid derivative | |
KR20150079665A (en) | Substituted indole derivatives | |
WO2014182688A1 (en) | Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto | |
JPH11292876A (en) | Polyaryl antitumor agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20091006 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
17Q | First examination report despatched |
Effective date: 20111122 |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20141001 |